Dynavax Technologies Corporation
(NASDAQ:DVAX)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older ...

Website: http://www.dynavax.com

Founded: 1996

Full Time Employees: 231

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30

revenues:
product revenue	89,954,000	91,872,000	64,959,000	71,053,000	79,345,000	70,188,000	47,845,000	51,086,000	62,318,000	56,440,000	43,451,000	182,183,000	163,815,000	255,320,000	112,327,000	194,541,000	106,996,000	52,677,000	82,885,000	13,112,000	13,276,000	2,405,000	10,514,000	10,558,000	10,158,000	8,301,000	5,627,000	3,932,000	1,461,000	1,254,000	165,000
other revenue	4,922,000	3,570,000	3,205,000	979,000	1,285,000	3,607,000	2,945,000	4,510,000	7,196,000	3,809,000	3,474,000	2,309,000	3,920,000	1,144,000	1,665,000	529,000	1,274,000	90,000	450,000	6,438,000	138,000	263,000	405,000	-131,000	417,000
total revenues	94,876,000	95,442,000	68,164,000	72,032,000	80,630,000	73,795,000	50,790,000	55,596,000	69,514,000	60,249,000	46,925,000	184,492,000	167,735,000	256,464,000	113,992,000	195,070,000	108,270,000	52,767,000	83,335,000	19,550,000	13,414,000	2,668,000	10,919,000	10,570,000	10,575,000	8,301,000	5,773,000	5,318,000	1,461,000	1,254,000	165,000	21,000	53,000	105,000	148,000	7,292,000	162,000	2,647,000	942,000	685,000	1,188,000	1,550,000	627,000	2,277,000	2,209,000	3,048,000	3,498,000	2,847,000	2,927,000	3,392,000	2,085,000	1,806,000	2,874,000	2,684,000	2,350,000	11,427,000	1,174,000	7,269,000	1,744,000	1,766,000	11,649,000	2,191,000	8,344,000	2,189,000	2,901,000	15,884,000	19,344,000	11,945,000	8,857,000	9,978,000	6,314,000	9,295,000	1,014,000	1,800,000	1,984,000	2,438,000	1,592,000	529,000	288,000	600,000	404,000	953,000	12,698,000	2,455,000	3,660,000	5,492,000
yoy	17.67%	29.33%	34.21%	29.56%	15.99%	22.48%	8.24%	-69.87%	-58.56%	-76.51%	-58.83%	-5.42%	54.92%	386.03%	36.79%	897.80%	707.14%	1877.77%	663.21%	84.96%	26.85%	-67.86%	89.14%	98.76%	623.82%	561.96%	3398.79%	25223.81%	2656.60%	1094.29%	11.49%	-99.71%	-67.28%	-96.03%	-84.29%	964.53%	-86.36%	70.77%	50.24%	-69.92%	-46.22%	-49.15%	-82.08%	-20.02%	-24.53%	-10.14%	67.77%	57.64%	1.84%	26.38%	-11.28%	-84.20%	144.80%	-63.08%	34.75%	547.06%	-89.92%	231.77%	-79.10%	-19.32%	301.55%	-86.21%	-56.87%	-81.67%	-67.25%	59.19%	206.37%	28.51%	773.47%	454.33%	218.25%	281.26%	-36.31%	240.26%	588.89%	306.33%	294.06%	-44.49%	-97.73%	-75.56%	-88.96%	-82.65%
qoq	-0.59%	40.02%	-5.37%	-10.66%	9.26%	45.29%	-8.64%	-20.02%	15.38%	28.39%	-74.57%	9.99%	-34.60%	124.98%	-41.56%	80.17%	105.19%	-36.68%	326.27%	45.74%	402.77%	-75.57%	3.30%	-0.05%	27.39%	43.79%	8.56%	264.00%	16.51%	660.00%	685.71%	-60.38%	-49.52%	-29.05%	-97.97%	4401.23%	-93.88%	181.00%	37.52%	-42.34%	-23.35%	147.21%	-72.46%	3.08%	-27.53%	-12.86%	22.87%	-2.73%	-13.71%	62.69%	15.45%	-37.16%	7.08%	14.21%	-79.43%	873.34%	-83.85%	316.80%	-1.25%	-84.84%	431.68%	-73.74%	281.18%	-24.54%	-81.74%	-17.89%	61.94%	34.87%	-11.23%	58.03%	-32.07%	816.67%	-43.67%	-9.27%	-18.62%	53.14%	200.95%	83.68%	-52.00%	48.51%	-57.61%	-92.49%	417.23%	-32.92%	-33.36%
operating expenses:
cost of sales - product	14,403,000	14,035,000	13,769,000	13,410,000	13,084,000	11,985,000	10,966,000	8,689,000	13,229,000	13,537,000	14,712,000	77,488,000	61,334,000	83,369,000	39,962,000	74,012,000	60,090,000	14,845,000	24,625,000	4,058,000	4,031,000	967,000	2,354,000	2,407,000	3,824,000	2,141,000	1,800,000	1,625,000	3,927,000	5,177,000	205,000
research and development	19,116,000	16,619,000	19,377,000	18,669,000	14,403,000	14,950,000	13,528,000	14,119,000	14,116,000	13,046,000	13,605,000	12,854,000	12,962,000	9,689,000	11,095,000	11,117,000	6,186,000	7,167,000	7,758,000	9,549,000	8,521,000	5,884,000	4,653,000	12,269,000	12,660,000	16,196,000	21,206,000	22,892,000	16,820,000	16,273,000	18,966,000	17,412,000	16,417,000	14,814,000	16,345,000	18,442,000	23,234,000	22,750,000	20,067,000	20,932,000	24,105,000	19,686,000	22,220,000	19,638,000	28,072,000	23,639,000	13,231,000	12,131,000	11,770,000	12,805,000	14,164,000	12,515,000	12,850,000	11,376,000	12,405,000	11,616,000	11,777,000	13,257,000	14,672,000	12,951,000	14,204,000	14,045,000	12,480,000	9,506,000	9,631,000	9,239,000	10,332,000	6,249,000	10,456,000	12,946,000	15,120,000	18,183,000	14,909,000	19,164,000	13,632,000	19,981,000	12,781,000	10,762,000	6,592,000	7,942,000	6,797,000	7,493,000	5,655,000	5,420,000	5,928,000	6,510,000
selling, general and administrative	40,086,000	50,359,000	47,678,000	41,585,000	43,061,000	41,662,000	44,065,000	41,279,000	38,053,000	37,071,000	36,543,000	31,015,000	32,042,000	36,179,000	32,172,000	29,224,000	26,926,000	21,583,000	22,423,000	17,838,000	21,538,000	18,954,000	20,926,000	20,318,000	18,459,000	17,861,000	18,348,000	16,438,000	15,788,000	15,653,000	16,891,000
bad debt expense			10,970,000								12,313,000
total operating expenses	73,605,000	81,013,000	91,794,000	73,664,000	70,548,000	68,597,000	68,559,000	64,087,000	64,398,000	63,654,000	77,173,000	121,357,000	106,338,000	128,237,000	83,229,000	114,353,000	92,202,000	43,595,000	54,806,000	31,445,000	27,239,000	26,007,000	30,231,000	37,959,000	41,204,000	47,272,000	43,627,000	43,279,000	40,358,000	39,401,000	38,479,000	27,862,000	22,444,000	20,426,000	25,600,000	26,613,000	35,000,000	31,901,000	28,236,000	27,631,000	29,629,000	24,784,000	27,079,000	24,690,000	32,286,000	27,902,000	17,465,000	15,839,000	18,495,000	20,441,000	22,964,000	21,808,000	19,971,000	17,333,000	18,198,000	16,161,000	15,994,000	17,365,000	19,671,000	17,381,000	18,400,000	18,463,000	17,295,000	13,803,000	13,612,000	13,017,000	15,001,000	10,053,000	14,614,000	16,611,000	19,936,000	23,312,000	20,189,000	23,622,000	18,063,000	24,429,000	17,688,000	18,518,000	9,195,000	10,068,000	9,116,000	9,966,000	7,995,000	7,950,000	7,945,000	8,587,000
income from operations	21,271,000	14,429,000	-23,630,000	-1,632,000	10,082,000	5,198,000	-17,769,000	-8,491,000	5,116,000	-3,405,000	-30,248,000	63,135,000	61,397,000	128,227,000	30,763,000	80,717,000	16,068,000	9,172,000	28,529,000	-11,895,000	-13,825,000	-23,339,000	-19,312,000	-27,389,000	-30,629,000	-38,971,000	-37,854,000	-37,961,000	-38,897,000	-38,147,000	-38,314,000	-27,841,000	-22,391,000	-20,321,000	-25,452,000	-19,321,000	-34,838,000	-29,254,000	-27,294,000	-26,946,000	-28,441,000	-23,234,000	-26,452,000	-22,413,000	-30,077,000	-24,854,000	-13,967,000	-12,992,000	-15,568,000	-17,049,000	-20,879,000	-20,002,000	-17,097,000	-14,649,000	-15,848,000	-4,734,000	-14,820,000	-10,096,000	-17,927,000	-15,615,000	-6,751,000	-16,272,000	-8,951,000	-11,614,000	-10,711,000	2,867,000	4,343,000	1,892,000	-5,757,000	-6,633,000	-13,622,000	-14,017,000	-19,175,000	-21,822,000	-16,079,000	-21,991,000	-16,096,000	-17,989,000	-8,907,000	-9,468,000	-8,712,000	-9,013,000	4,703,000	-5,495,000	-4,285,000	-3,095,000
yoy	110.98%	177.59%	32.98%	-80.78%	97.07%	-252.66%	-41.26%	-113.45%	-91.67%	-102.66%	-198.33%	-21.78%	282.11%	1298.03%	7.83%	-778.58%	-216.22%	-139.30%	-247.73%	-56.57%	-54.86%	-40.11%	-48.98%	-27.85%	-21.26%	2.16%	-1.20%	36.35%	73.72%	87.72%	50.53%	44.10%	-35.73%	-30.54%	-6.75%	-28.30%	22.49%	25.91%	3.18%	20.22%	-5.44%	-6.52%	89.39%	72.51%	93.20%	45.78%	-33.11%	-35.05%	-8.94%	16.38%	31.75%	322.52%	15.36%	45.10%	-11.60%	-69.68%	119.52%	-37.95%	100.28%	34.45%	-36.97%	-667.56%	-306.10%	-713.85%	86.05%	-143.22%	-131.88%	-113.50%	-69.98%	-69.60%	-15.28%	-36.26%	19.13%	21.31%	80.52%	132.27%	84.76%	99.59%	-289.39%	72.30%	103.31%	191.21%
qoq	47.42%	-161.06%	1347.92%	-116.19%	93.96%	-129.25%	109.27%	-265.97%	-250.25%	-88.74%	-147.91%	2.83%	-52.12%	316.82%	-61.89%	402.35%	75.19%	-67.85%	-339.84%	-13.96%	-40.76%	20.85%	-29.49%	-10.58%	-21.41%	2.95%	-0.28%	-2.41%	1.97%	-0.44%	37.62%	24.34%	10.19%	-20.16%	31.73%	-44.54%	19.09%	7.18%	1.29%	-5.26%	22.41%	-12.17%	18.02%	-25.48%	21.01%	77.95%	7.50%	-16.55%	-8.69%	-18.34%	4.38%	16.99%	16.71%	-7.57%	234.77%	-68.06%	46.79%	-43.68%	14.81%	131.30%	-58.51%	81.79%	-22.93%	8.43%	-473.60%	-33.99%	129.55%	-132.86%	-13.21%	-51.31%	-2.82%	-26.90%	-12.13%	35.72%	-26.88%	36.62%	-10.52%	101.96%	-5.93%	8.68%	-3.34%	-291.64%	-185.59%	28.24%	38.45%
operating margin %	22.42%	15.12%	-34.67%	-2.27%	12.50%	7.04%	-34.99%	-15.27%	7.36%	-5.65%	-64.46%	34.22%	36.60%	50.00%	26.99%	41.38%	14.84%	17.38%	34.23%	-60.84%	-103.06%	-874.78%	-176.87%	-259.12%	-289.64%	-469.47%	-655.71%	-713.82%	-2662.35%	-3042.03%	-23220.61%	-132576.19%	-42247.17%	-19353.33%	-17197.30%	-264.96%	-21504.94%	-1105.18%	-2897.45%	-3933.72%	-2394.02%	-1498.97%	-4218.82%	-984.32%	-1361.57%	-815.42%	-399.29%	-456.34%	-531.88%	-502.62%	-1001.39%	-1107.53%	-594.89%	-545.79%	-674.38%	-41.43%	-1262.35%	-138.89%	-1027.92%	-884.20%	-57.95%	-742.67%	-107.27%	-530.56%	-369.22%	18.05%	22.45%	15.84%	-65.00%	-66.48%	-215.74%	-150.80%	-1891.03%	-1212.33%	-810.43%	-902.01%	-1011.06%	-3400.57%	-3092.71%	-1578.00%	-2156.44%	-945.75%	37.04%	-223.83%	-117.08%	-56.35%
other income:
interest income	6,593,000	6,798,000	7,739,000	8,414,000	9,382,000	9,201,000	9,468,000	9,556,000	8,462,000	7,378,000	6,597,000	4,324,000	2,562,000	765,000	261,000	6,000	39,000	48,000	47,000	70,000	269,000	331,000	590,000	766,000	890,000	979,000	735,000	888,000	1,047,000	1,153,000	740,000	528,000	429,000	235,000	145,000	140,000	170,000	220,000	225,000	127,000	33,000	18,000	27,000	29,000	42,000	55,000	65,000	-47,000	37,000	54,000	72,000	83,000	91,000	65,000	52,000	29,000	18,000	23,000	33,000	32,000	12,000	39,000	2,000	43,500	18,000	46,000	110,000												735,000	706,000	428,000	434,000	367,000	332,000	252,000	186,000
interest expense	-1,643,000	-1,641,000	-1,692,000	-1,704,000	-1,699,000	-1,698,000	-1,695,000	-1,692,000	-1,691,000	-1,688,000	-1,686,000	-1,684,000	-1,685,000	-1,683,000	-1,680,000	-1,679,000	-1,676,000	-3,109,000	-4,712,000	-4,805,000	-4,794,000	-4,732,000	-4,731,000	-4,866,000	-4,779,000	-4,598,000	-2,734,000	-2,751,000	-2,735,000	-2,691,000	-1,161,000										-62,000	-263,000	-247,000					-20,750	-24,000	-27,000	-32,000	-586,000	-589,000	-589,000	-587,000	-495,000	-485,000	-487,000	-490,000	-425,000	-399,000	-431,000	-399,000	-4,000	-93,000	-12,000	-15,000	-16,000	-6,457,000	-1,340,000	-1,344,000
sublease income	2,225,000	2,226,000	2,226,000	2,206,000	2,205,000	2,205,000	-1,602,000	1,993,000	1,993,000	1,993,000	1,598,000	2,025,000	2,026,000	2,025,000	1,609,000	2,021,000	2,022,000	1,670,000	2,022,000	1,927,000	1,926,000	1,927,000	1,926,000	1,728,000	891,000
loss on debt extinguishment			-82,095,000															-5,232,000
other loss	-27,000
net income before income taxes	28,419,000	21,216,000		7,629,000	19,818,000	14,906,000		996,000	14,146,000	4,207,000	-23,716,000	56,581,250	64,092,000	129,374,000
provision for income taxes	-1,492,000	-2,495,000				-3,520,000				-776,000	-616,000	-241,000	-283,000	-619,000
net income	26,927,000	18,721,000	-96,099,000	7,050,000	17,594,000	11,386,000	-8,721,000	219,000	14,293,000	3,431,000	-24,332,000	67,733,000	63,809,000	128,755,000	32,859,000	99,779,000	-28,430,000	4,473,000	891,000	-15,467,000	4,401,000	-51,579,000	-12,595,000	-36,756,000	-33,459,000	-42,713,000	-39,672,000	-39,969,000	-40,528,000	-39,444,000	-38,958,000	-27,421,000	-22,128,000	-20,318,000	-25,287,000	-21,741,000	-34,694,000	-28,986,000	-27,023,000	-26,862,000	-30,124,000	-23,591,000	-26,217,000	-22,286,000	-29,819,000	-24,777,000	-13,840,000	-13,056,000	-15,675,000	-17,164,000	-20,825,000	-20,543,000	-17,791,000	-15,110,000	-16,505,000	-4,267,000	-15,229,000	-10,635,000	-18,466,000	-15,122,000	-4,998,000	-28,004,000	-9,184,000	-11,640,000	-10,706,000	3,127,000	4,092,000	3,099,000	-5,420,000	-6,079,000	-12,429,000	-12,076,000	-17,101,000	-17,704,000	-13,090,000	-16,455,000	-12,152,000	-15,273,000	-8,172,000	-8,762,000	-8,284,000	-8,579,000	5,070,000	-5,163,000	-4,033,000	-2,909,000
yoy	53.05%	64.42%	1001.93%	3119.18%	23.10%	231.86%	-64.16%	-99.68%	-77.60%	-97.34%	-174.05%	-32.12%	-324.44%	2778.49%	3587.88%	-745.11%	-745.99%	-108.67%	-107.07%	-57.92%	-113.15%	20.76%	-68.25%	-8.04%	-17.44%	8.29%	1.83%	45.76%	83.15%	94.13%	54.06%	26.13%	-36.22%	-29.90%	-6.42%	-19.06%	15.17%	22.87%	3.07%	20.53%	1.02%	-4.79%	89.43%	70.70%	90.23%	44.35%	-33.54%	-36.45%	-11.89%	13.59%	26.17%	381.44%	16.82%	42.08%	-10.62%	-71.78%	204.70%	-62.02%	101.07%	29.91%	-53.32%	-995.55%	-324.44%	-475.61%	97.53%	-151.44%	-132.92%	-125.66%	-68.31%	-65.66%	-5.05%	-26.61%	40.73%	15.92%	60.18%	87.80%	46.69%	78.03%	-261.18%	69.71%	105.41%	194.91%
qoq	43.83%	-119.48%	-1463.11%	-59.93%	54.52%	-230.56%	-4082.19%	-98.47%	316.58%	-114.10%	-135.92%	6.15%	-50.44%	291.84%	-67.07%	-450.96%	-735.59%	402.02%	-105.76%	-451.44%	-108.53%	309.52%	-65.73%	9.85%	-21.67%	7.67%	-0.74%	-1.38%	2.75%	1.25%	42.07%	23.92%	8.91%	-19.65%	16.31%	-37.33%	19.69%	7.26%	0.60%	-10.83%	27.69%	-10.02%	17.64%	-25.26%	20.35%	79.02%	6.00%	-16.71%	-8.68%	-17.58%	1.37%	15.47%	17.74%	-8.45%	286.81%	-71.98%	43.20%	-42.41%	22.11%	202.56%	-82.15%	204.92%	-21.10%	8.72%	-442.37%	-23.58%	32.04%	-157.18%	-10.84%	-51.09%	2.92%	-29.38%	-3.41%	35.25%	-20.45%	35.41%	-20.43%	86.89%	-6.73%	5.77%	-3.44%	-269.21%	-198.20%	28.02%	38.64%
net income margin %	28.38%	19.62%	-140.98%	9.79%	21.82%	15.43%	-17.17%	0.39%	20.56%	5.69%	-51.85%	36.71%	38.04%	50.20%	28.83%	51.15%	-26.26%	8.48%	1.07%	-79.12%	32.81%	-1933.25%	-115.35%	-347.74%	-316.40%	-514.55%	-687.20%	-751.58%	-2773.99%	-3145.45%	-23610.91%	-130576.19%	-41750.94%	-19350.48%	-17085.81%	-298.15%	-21416.05%	-1095.05%	-2868.68%	-3921.46%	-2535.69%	-1522.00%	-4181.34%	-978.74%	-1349.89%	-812.89%	-395.65%	-458.59%	-535.53%	-506.01%	-998.80%	-1137.49%	-619.03%	-562.97%	-702.34%	-37.34%	-1297.19%	-146.31%	-1058.83%	-856.29%	-42.90%	-1278.14%	-110.07%	-531.75%	-369.05%	19.69%	21.15%	25.94%	-61.19%	-60.92%	-196.85%	-129.92%	-1686.49%	-983.56%	-659.78%	-674.94%	-763.32%	-2887.15%	-2837.50%	-1460.33%	-2050.50%	-900.21%	39.93%	-210.31%	-110.19%	-52.97%
net income per share																								-0.41	-0.49
basic	0.23	0.16	-0.77	0.06	0.13	0.09	-0.07		0.11	0.03	-0.19	0.53	0.5	1.02	0.26	0.82	-0.24	0.04	0.01
diluted	0.21	0.14	-0.77	0.05	0.12	0.08	-0.07		0.1	0.03	-0.19	0.46	0.43	0.87	0.22	0.77	-0.24	0.02	0.01
weighted-average shares used for eps calculation																				100,753	109,816	97,339	85,477	72,024	75,106	65,088	63,778	62,362	62,650	62,346	61,744	52,613	57,650	49,700	41,830	38,506	38,512	38,496	38,472		36,532	29,335							183,022	182,913
basic	117,307	119,317	124,871	130,047	131,133	130,916	130,200	128,733	128,988	128,625	127,921	126,398	127,062	126,347	124,555	116,264	116,903	114,629	112,035
diluted	136,468	138,356	124,871	133,344	154,807	154,468	130,200	128,733	154,196	152,142	127,921	150,797	151,538	149,905	149,425	133,006	116,903	118,830	113,469
other income		-596,000	-423,000																				322,000	505,000	168,000	-123,000	181,000	18,750	57,000	241,000	-223,000	-108,000	-166,000	-232,000	20,000	-2,560,000	-26,000	48,000	46,000	-43,000	17,000	-112,000	455,000	133,000	216,000	22,000	62,000	-100,000	-120,000	-142,000	14,000	-38,000	-196,000	63,000	-122,000	933,000	58,000	-75,000	-82,000	886,000	2,140,000	-11,340,000	164,000	-10,000	80,000	226,000	-346,000
net loss before income taxes			-97,875,000				-11,497,000
benefit from income taxes			1,776,000	-741,750	-2,224,000		2,776,000	-311,250	147,000
gain on sale of assets									-1,000,000					-1,000,000			-1,000,000				-6,851,000
other				345,000	-152,000		101,000	-370,000	266,000	-71,000	23,000	174,000	-208,000	40,000	105,000	300,000	238,000	-173,000	557,000	-688,000	-420,000	-111,000
change in fair value of warrant liability															1,801,000	19,222,000	-45,121,000	2,097,000	-25,552,000	-76,000	21,245,000	-25,655,000	8,610,000
cost of sales - amortization of intangible assets																						202,000	2,298,000	2,323,000	2,324,000	2,297,000	2,273,000	2,324,000	3,823,000	2,298,000	2,417,000
restructuring																								642,000	3,937,000	8,777,000									2,783,000
preferred stock deemed dividend																									-3,267,000
net income allocable to common stockholders																				-15,467,000	4,401,000
basic net income per share allocable to common stockholders																				-0.14	0.04
weighted-average shares used for eps calculation																				100,753	109,816	97,339	85,477	72,024	75,106	65,088	63,778	62,362	62,650	62,346	61,744	52,613	57,650	49,700	41,830	38,506	38,512	38,496	38,472		36,532	29,335							183,022	182,913
diluted net loss per share allocable to common stockholders																				-0.163	-0.15
basic and diluted net loss per share																						-0.53				-0.66	-0.62	-0.64	-0.65	-0.63
basic net loss per share																							-0.15
diluted net loss per share																							-0.25
net loss allocable to common stockholders																								-36,756,000	-36,726,000
net income per share																								-0.41	-0.49
collaboration revenue																											146,000									7,200,000		1,683,000	895,000	535,000	829,000	930,000	471,000	1,734,000	1,795,000	2,031,000	2,373,000	1,580,000	1,110,000	1,356,000	883,000	1,008,000	1,050,000	1,623,000	929,000	10,092,000	369,000	6,363,000	366,000	371,000	10,402,000	1,341,000	7,421,000	1,455,000	1,791,000	14,596,000	17,692,000	10,231,000	7,960,000	7,701,000	5,774,000	7,097,000	719,000	752,000	747,000	1,391,000	166,000						12,199,000	2,138,000	3,769,000	5,131,000
grant revenue																																-11,000	53,000	105,000	148,000	92,000	162,000	88,000	39,000	75,000	359,000	101,000	148,000	142,000	414,000	1,007,000	1,125,000	1,283,000	1,700,000	1,395,000	760,000	751,000	1,219,000	882,000	1,087,000	673,000	658,000	890,000	889,000	1,243,000	1,218,000	617,000	862,000	556,000	887,000	895,000	1,139,000	972,000	581,000	1,122,000	324,000	1,198,000	133,000	587,000	1,128,000	222,000	734,000	305,000	288,000	600,000	404,000	953,000	499,000	317,000	-109,000	361,000
basic and diluted net income per share																															-0.63	-0.45	-0.38	-0.41	-0.6	-0.56	-0.9	-0.75	-0.7	-0.608	-0.82	-0.8	-0.97	-0.065	-0.11	-0.09	-0.05	-0.073	-0.09	-0.09	-0.11	-0.11	-0.1	-0.09	-0.11	-0.093	-0.12	-0.09	-0.16									0.08	-0.14	-0.15	-0.31	-0.3	-0.43	-0.45	-0.33	-0.44	-0.4	-0.5		-0.12	-0.33	-0.35		-0.135	-0.16	-0.12
service and license revenue																																						876,000	8,000	75,000		519,000	8,000	401,000		10,000		-16,000	117,000	641,000	442,000	47,000	605,000	179,000	334,000	662,000	147,000	16,000	489,000	152,000	29,000	233,000	61,000	178,000	223,000	393,000	513,000	742,000	316,000	1,155,000	216,000
general and administrative																																4,527,750	6,027,000	5,612,000	6,472,000	8,171,000	11,766,000	9,151,000	8,169,000	6,699,000	5,524,000	5,098,000	4,859,000	5,052,000	4,083,000	4,085,000	4,157,000	3,700,000	5,807,000	7,636,000	8,800,000	9,293,000	7,121,000	5,957,000	5,793,000	4,545,000	4,217,000	4,054,000	4,754,000	4,185,000	3,951,000	4,173,000	4,570,000	4,052,000	3,736,000	3,533,000	4,424,000	3,559,000	3,913,000	3,420,000	4,571,000	4,879,000	5,029,000	4,206,000	4,180,000	4,197,000	4,656,000	3,380,000	2,603,000	2,126,000	2,319,000	2,473,000	2,340,000	2,530,000	2,017,000	2,077,000
loss on extinguishment of debt																																									-1,671,000
unoccupied facility expense																																													131,000	178,000	77,000	8,000	918,000
weighted-average number of shares used to compute basic and diluted net income per share																																											27,065		262,908	262,861	262,826
shares used to compute basic and diluted net income per share																																																			182,847	3,430	177,870	167,697	155,431	29,811	124,069	117,864	115,726									12	39,831	39,806	39,785	6	39,753	39,741	39,727	1,788	30,605	30,536		6,185	24,751	24,745		5,008.5	24,609	24,594
amortization of intangible assets																																																										54,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	250,000	251,000	252,000	251,000	251,000	251,000	196,000
add: losses attributable to noncontrolling interest in symphony dynamo inc.
net income attributable to dynavax																																																												-15,122,000	-4,998,000	-28,004,000	-9,184,000	-30,270,000	-9,506,000	4,110,000	5,101,000
basic and diluted net income per share attributable to dynavax common stockholders																																																												-0.12	-0.06		-0.17				0.13
shares used to compute basic and diluted net income per share attributable to dynavax common stockholders																																																												7,944	86,826		54,364	360	40,153		39,889
basic net income per share attributable to dynavax common stockholders																																																														-0.34		-0.003	-0.24	0.1
shares used to compute basic net income per share attributable to dynavax common stockholders																																																														82,012				39,923
diluted net income per share attributable to dynavax common stockholders																																																														-0.34				0.1
shares used to compute diluted net income per share attributable to dynavax common stockholders																																																														82,012				40,064
add: losses attributable to noncontrolling interest in sdi																																																																1,041,000	1,200,000	983,000	1,009,000
loan forgiveness																																																																					5,000,000
interest and other income																																																																				284,000	81,000	405,000	971,000	1,659,000	453,000	1,081,000	973,000	1,095,000	673,000	685,000
loss including noncontrolling interest in sdi																																																																				2,160,000	-7,133,000
amount attributed to noncontrolling interest in sdi																																																																				939,000	1,713,000
loss including noncontrolling interest in symphony dynamo, inc.																																																																						-7,568,000	-13,995,000	-14,077,000	-18,722,000	-20,741,000	-15,106,000	-20,896,000	-15,423,000	-17,304,000
amount attributed to noncontrolling interest in symphony dynamo, inc.																																																																						1,489,000	1,566,000	2,001,000	1,621,000	3,037,000	2,016,000
services and license revenue																																																																								183,000	162,000	461,000	109,000	229,000	692,000	224,000
acquired in-process research and development																																																																														4,180,000
loss attributed to noncontrolling interest in symphony dynamo, inc.																																																																												1,325,500	3,271,000	2,031,000
basic net income per share																																																																															-0.27				0.21
shares used to compute basic net income per share																																																																															30,487				24,722
diluted net income per share																																																																															-0.27				0.2
shares used to compute diluted net income per share																																																																															30,487				24,837

Balance Sheets:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30

assets
current assets:
cash and cash equivalents	160,247,000	99,101,000	51,720,000	95,883,000	119,332,000	112,501,000	132,033,000	150,279,000	154,511,000	226,823,000	174,350,000	202,004,000	198,576,000	249,091,000	179,421,000	436,189,000	246,351,000	129,608,000	79,055,000	32,073,000	32,688,000	60,485,000	37,899,000	39,884,000	37,297,000	34,225,000	112,133,000	49,348,000	38,712,000	28,726,000	36,067,000	26,584,000	20,096,000	37,675,000	21,472,000	24,289,000	23,021,000	24,787,000	38,858,000	44,812,000	103,031,000	36,486,000	14,713,000	49,511,000	19,656,000	17,032,000	26,750,000	23,122,000	12,191,000	17,585,000	25,016,000	7,599,000	24,650,000	34,530,000	19,753,000	31,941,000	19,072,000	27,479,000	20,971,000	22,453,000	28,209,000	29,053,000	30,080,000	36,720,000	24,735,000	23,759,000	22,920,000	28,103,000	22,618,000	14,870,000	15,858,000	14,293,000	14,642,000	6,503,000	12,979,000	14,154,000	15,951,000	10,090,000	16,842,000	8,725,000	19,168,000	5,116,000	11,401,000	16,590,000	71,514,000	73,959,000
marketable securities available-for-sale	487,568,000	514,628,000	609,616,000	617,951,000	644,660,000	623,111,000	591,505,000	592,023,000	565,905,000	454,702,000	477,606,000	422,391,000	387,910,000	269,078,000	323,795,000	109,761,000	167,804,000	216,196,000	153,619,000	132,963,000	144,473,000	140,223,000	91,634,000	111,171,000	137,649,000	106,269,000	71,083,000	96,188,000	141,509,000	187,317,000	214,713,000	165,270,000	171,584,000	89,286,000	63,884,000	57,126,000	86,530,000	114,202,000	127,989,000	151,313,000	117,666,000	56,895,000	82,881,000	73,141,000	110,916,000	137,281,000	150,929,000	166,254,000	64,283,000	71,576,000	80,357,000	117,531,000	123,629,000	125,669,000	87,128,000														14,958,000	20,216,000	27,828,000		21,279,000	40,977,000	49,744,000
accounts receivables, net of allowance for doubtful accounts of 0 and 12,313 at september 30, 2025 and december 31, 2024, respectively	72,359,000
other receivables	962,000	2,646,000	1,632,000	1,625,000	1,943,000	976,000	1,993,000	3,926,000	519,000	2,108,000	3,128,000	2,385,000	1,346,000	1,972,000	2,968,000	15,600,000
inventories	73,288,000	75,687,000	74,403,000	70,054,000	62,402,000	62,462,000	61,806,000	53,290,000	49,412,000	53,088,000	57,693,000	59,446,000	102,609,000	73,979,000	79,038,000	61,335,000	67,297,000	86,451,000	68,846,000	63,689,000	59,033,000	54,392,000	48,099,000	41,332,000	39,356,000	36,629,000	27,569,000	19,022,000	12,452,000	5,112,000	550,000	312,000
prepaid expenses and other current assets	19,907,000	22,951,000	23,674,000	18,147,000	24,570,000	21,308,000	19,788,000	18,995,000	18,972,000	17,494,000	15,626,000	85,629,000	100,004,000	134,538,000	82,995,000	73,764,000	61,093,000	9,453,000	9,377,000	9,206,000	18,786,000	9,463,000	8,380,000	7,380,000	5,711,000	6,745,000	5,948,000	6,102,000	4,604,000	3,883,000	3,303,000	3,697,000	4,633,000	4,434,000	2,831,000	6,842,000	5,673,000	6,273,000	2,728,000	2,427,000	2,489,000	3,858,000	3,478,000	4,058,000	3,578,000	4,978,000	2,323,000	1,375,000	1,120,000	1,241,000	1,217,000	2,052,000	2,419,000	4,145,000	1,868,000	1,130,000	1,393,000	1,788,000	1,515,000	1,360,000	1,079,000	817,000	802,000	586,000	1,008,000	1,231,000	1,098,000	991,000	1,351,000	5,138,000	5,205,000	6,049,000	3,529,000	1,760,000	1,682,000	673,000	1,117,000	1,275,000	2,704,000	1,277,000	1,806,000	2,136,000	2,117,000	1,396,000	1,043,000	930,000
total current assets	814,331,000	785,712,000	815,970,000	848,941,000	926,241,000	882,012,000	851,286,000	859,120,000	835,666,000	797,460,000	830,141,000	916,985,000	932,944,000	955,405,000	940,515,000	972,520,000	852,670,000	583,906,000	427,533,000	290,015,000	290,003,000	265,466,000	194,147,000	208,653,000	228,835,000	191,450,000	222,524,000	174,364,000	198,784,000	226,342,000	255,396,000	198,023,000	197,096,000	132,205,000	89,652,000	89,599,000	117,514,000	147,126,000	170,739,000	199,946,000	224,349,000	97,896,000	101,981,000	127,437,000	134,877,000	160,583,000	181,732,000	192,378,000	79,753,000	92,427,000	108,137,000	128,187,000	154,383,000	165,628,000	110,124,000	124,618,000	55,397,000	64,651,000	55,845,000	74,515,000	50,224,000	60,177,000	32,690,000	38,882,000	49,301,000	56,457,000	65,218,000	76,542,000	72,502,000	77,009,000	85,167,000	101,939,000	73,499,000	86,096,000	74,886,000	89,686,000	62,331,000	63,140,000	71,024,000	77,484,000	54,004,000	61,522,000	68,906,000	70,779,000	76,509,000	79,538,000
property and equipment	45,855,000	45,610,000	43,272,000	39,001,000	37,420,000	36,105,000	36,413,000	37,297,000	36,183,000	37,442,000	38,159,000	37,596,000	35,352,000	36,286,000	36,407,000	35,020,000	34,251,000	32,547,000	30,696,000	30,567,000	30,379,000	30,476,000	30,897,000	32,022,000	31,461,000	34,393,000	25,305,000	17,064,000	16,933,000	16,240,000	17,064,000	16,619,000	16,622,000	16,751,000	16,633,000	17,174,000	18,739,000	17,448,000	15,894,000	13,804,000	11,606,000	8,887,000	7,528,000	7,924,000	8,129,000	8,789,000	8,584,000	8,706,000	8,454,000	8,038,000	7,972,000	7,965,000	6,948,000	6,833,000	6,962,000	6,163,000	6,127,000	6,570,000	6,516,000	6,404,000	6,634,000	6,324,000	7,199,000	7,997,000	8,507,000	8,610,000	8,600,000	9,510,000	10,241,000	11,165,000	10,268,000	7,314,000	6,380,000	6,040,000	5,552,000	5,200,000	4,918,000	4,986,000	2,035,000	2,197,000	2,286,000	2,405,000	2,344,000	2,465,000	2,157,000	1,065,000
operating lease right-of-use assets	19,904,000	20,314,000	20,869,000	21,608,000	21,780,000	22,526,000	23,392,000	24,287,000	24,949,000	25,366,000	25,433,000	25,745,000	25,680,000	25,785,000	26,310,000	25,964,000	26,772,000	25,164,000	25,799,000	26,583,000	27,353,000	27,871,000	28,436,000	30,252,000	29,723,000	29,533,000	33,505,000
goodwill	2,199,000	2,200,000	2,027,000	1,946,000	2,091,000	2,007,000	2,022,000	2,067,000	1,981,000	2,039,000	2,038,000	2,006,000	1,835,000	1,958,000	2,082,000	2,125,000	2,171,000	2,225,000	2,197,000	2,297,000	2,196,000	2,103,000	2,061,000	2,081,000	2,045,000	2,131,000	2,102,000	2,144,000	2,174,000	2,189,000	2,309,000	2,244,000	2,213,000	2,140,000	2,001,000	1,971,000	2,100,000	2,080,000	2,127,000	2,043,000	2,106,000	2,078,000	2,032,000	2,277,000	2,376,000	2,557,000	2,576,000	2,579,000	2,532,000	2,436,000	2,400,000	2,475,000	2,408,000	2,356,000	2,498,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000	2,312,000
other assets, net of allowance for doubtful accounts of 10,970 at september 30, 2025	64,217,000
total assets	946,506,000	918,449,000	945,928,000	986,256,000	1,061,990,000	1,016,321,000	986,565,000	997,096,000	972,933,000	936,432,000	969,922,000	985,850,000	999,337,000	1,022,999,000	1,008,975,000	1,039,246,000	919,711,000	647,909,000	490,119,000	353,272,000	353,395,000	329,314,000	259,256,000	279,068,000	301,015,000	267,081,000	296,600,000	210,884,000	236,388,000	263,863,000	295,333,000	218,785,000	217,827,000	151,968,000	110,132,000	109,680,000	139,298,000	167,613,000	189,644,000	216,633,000	238,907,000	109,494,000	112,169,000	138,290,000	146,896,000	173,465,000	193,585,000	204,622,000	91,698,000	104,012,000	119,621,000	139,752,000	164,822,000	175,895,000	120,676,000	134,102,000	64,719,000	74,430,000	65,507,000	84,249,000	61,790,000	71,678,000	44,284,000	50,470,000	61,644,000	69,148,000	78,144,000	90,623,000	87,559,000	96,938,000	105,332,000	120,449,000	87,996,000	98,482,000	87,033,000	102,890,000	75,498,000	76,624,000	73,471,000	80,093,000	56,702,000	64,339,000	71,250,000	73,646,000	79,073,000	81,014,000
liabilities and stockholders’ equity
current liabilities:
accounts payable	3,948,000	2,702,000	4,330,000	9,061,000	7,089,000	4,555,000	2,431,000	5,245,000	3,120,000	3,246,000	7,296,000	3,211,000	3,050,000	4,959,000	20,194,000	2,600,000	3,596,000	12,079,000	3,154,000	3,312,000	5,273,000	2,695,000	4,557,000	9,278,000	7,660,000	11,226,000	11,868,000	5,278,000	4,089,000	3,314,000	2,279,000	4,539,000	2,243,000	681,000	1,466,000	3,796,000	3,795,000	4,486,000	3,476,000	3,433,000	2,359,000	2,345,000	3,272,000	1,159,000	4,972,000	1,900,000	1,863,000	1,901,000	1,289,000	1,253,000	1,727,000	2,166,000	1,578,000	1,155,000	2,358,000	2,040,000	1,313,000	1,742,000	1,880,000	2,329,000	2,067,000	1,033,000	1,091,000	1,686,000	1,037,000	1,222,000	1,088,000	905,000	1,130,000	1,379,000	2,764,000	4,418,000	1,951,000	3,405,000	1,564,000	2,181,000	3,108,000	1,417,000	896,000	952,000	2,259,000	1,620,000	729,000	1,391,000	2,059,000	2,161,000
accrued research and development	6,697,000	5,459,000	5,654,000	4,310,000	4,402,000	4,581,000	3,137,000	2,982,000	3,290,000	3,594,000	5,155,000	4,775,000	4,300,000	3,678,000	6,359,000	4,688,000	3,935,000	4,167,000	2,890,000	2,805,000	2,939,000	2,396,000	3,253,000	4,120,000	4,242,000	5,501,000	9,630,000	9,714,000	6,003,000	4,121,000	4,443,000	4,359,000	3,079,000	3,223,000	4,305,000	5,048,000	4,702,000	5,273,000	6,027,000	7,361,000	7,861,000	5,927,000	7,346,000	6,938,000	6,801,000	6,720,000
accrued liabilities	51,889,000	65,952,000	54,292,000	61,066,000	54,102,000	48,488,000	45,841,000	49,448,000	43,462,000	33,872,000	27,833,000	30,719,000	38,209,000	34,146,000	16,108,000	49,796,000	87,910,000	25,711,000	16,083,000	19,099,000	17,192,000	13,181,000	12,268,000	14,802,000	17,003,000	19,550,000	12,384,000	16,041,000	14,506,000	11,087,000	9,820,000	9,695,000	7,567,000	7,184,000	6,607,000	11,192,000	21,988,000	18,464,000	13,251,000	15,337,000	5,952,000	4,746,000	3,593,000	6,317,000			6,608,000	8,166,000	8,148,000	7,307,000	8,166,000	10,063,000	9,163,000	7,340,000	6,301,000	8,159,000	7,316,000	7,113,000	8,158,000	10,943,000	17,530,000	14,644,000	10,571,000	7,507,000	7,356,000	6,682,000	6,878,000	6,816,000	11,976,000	10,381,000	10,267,000	12,059,000	11,075,000	9,636,000	9,788,000	10,742,000	6,930,000	6,195,000	4,709,000	3,841,000	3,910,000	4,549,000	4,240,000	4,371,000	4,885,000	3,235,000
convertible notes, current portion, net of debt discount of 135 at september 30, 2025	40,073,000
other current liabilities	4,232,000	4,097,000	4,103,000	4,197,000	4,437,000	4,568,000	4,593,000	4,520,000	4,392,000	4,150,000	3,830,000	3,631,000	3,388,000	3,047,000	2,969,000	2,590,000	2,889,000	3,489,000	3,356,000	3,247,000	8,849,000	3,045,000	2,951,000	9,987,000	9,849,000	8,296,000	8,369,000	7,000,000	7,000,000	7,000,000	7,000,000
total current liabilities	106,839,000	118,230,000	68,379,000	78,634,000	70,030,000	62,192,000	56,002,000	62,195,000	54,264,000	44,862,000	91,515,000	150,074,000	244,080,000	345,198,000	466,203,000	556,402,000	528,935,000	204,642,000	109,422,000	77,411,000	66,625,000	53,222,000	29,279,000	53,047,000	46,348,000	44,573,000	42,251,000	38,033,000	31,598,000	25,522,000	23,542,000	18,593,000	12,889,000	11,088,000	12,378,000	20,036,000	30,485,000	28,223,000	24,513,000	28,785,000	19,730,000	21,964,000	20,499,000	20,279,000	22,820,000	20,183,000	15,982,000	16,192,000	15,563,000	14,906,000	17,060,000	19,014,000	29,365,000	25,259,000	25,817,000	27,219,000	10,058,000	10,284,000	11,467,000	14,701,000	21,026,000	29,135,000	16,361,000	14,478,000	11,520,000	11,576,000	24,120,000	40,854,000	19,890,000	15,442,000	16,547,000	19,904,000	13,807,000	13,589,000	12,100,000	13,701,000	11,465,000	8,441,000	6,355,000	5,543,000	6,169,000	6,217,000	4,969,000	6,762,000	8,694,000	7,146,000
convertible notes, net of debt discount of 4,034 and 1,646 at september 30, 2025 and december 31, 2024, respectively	220,966,000
long-term portion of lease liabilities	23,985,000	24,726,000	25,521,000	26,388,000	26,607,000	27,473,000	28,559,000	29,720,000	30,680,000	31,545,000	32,131,000	32,801,000	33,127,000	33,677,000	34,253,000	34,316,000	34,929,000	32,897,000	33,795,000	34,789,000	35,519,000	36,231,000	36,972,000	37,845,000	36,964,000	34,641,000	35,076,000
cepi accrual long-term	60,337,000	60,337,000	60,337,000	60,337,000	60,337,000	60,337,000	60,337,000	60,337,000	60,337,000	60,337,000	60,337,000
other long-term liabilities	241,000	242,000	243,000	244,000	28,000	198,000	203,000	74,000	321,000	349,000	352,000	384,000	251,000	295,000	276,000	5,664,000	79,000	81,000	2,901,000	2,568,000	2,234,000	1,910,000	1,598,000	1,285,000	932,000	643,000	441,000	8,915,000	7,458,000	7,257,000	6,672,000	643,000	504,000	353,000	358,000	443,000	541,000	620,000	700,000	769,000	1,001,000	1,125,000	1,085,000	1,070,000	1,645,000	902,000	927,000	963,000	988,000	627,000	621,000	629,000	624,000	616,000	631,000	617,000	630,000				60,000	65,000	146,000	151,000	160,000	166,000	117,000	101,000	106,000	7,611,000	7,616,000	5,622,000	3,627,000	82,000	99,000	117,000	135,000	152,000	170,000	187,000	205,000	222,000	240,000	258,000
total liabilities	412,368,000	424,287,000	414,987,000	389,457,000	380,563,000	373,472,000	368,085,000	375,024,000	368,017,000	359,227,000	406,190,000	404,837,000	498,761,000	600,200,000	721,491,000	816,872,000	852,135,000	564,529,000	390,357,000	294,579,000	284,111,000	271,019,000	247,432,000	270,778,000	261,859,000	256,493,000	253,441,000	147,819,000	139,375,000	132,550,000	129,446,000	19,236,000	13,393,000	11,441,000	12,736,000	20,479,000	31,026,000	28,843,000	25,213,000	29,554,000	27,719,000	34,966,000	37,096,000	37,808,000	25,320,000	22,795,000	19,732,000	18,328,000	19,302,000	19,353,000	21,694,000	24,926,000	34,764,000
commitments and contingencies
stockholders’ equity:
preferred stock: 0.001 par value...
common stock: 0.001 par value...	117,000	117,000	124,000	125,000	131,000	131,000	131,000	130,000	129,000	129,000	128,000	128,000	127,000	126,000	126,000	123,000	120,000	114,000	114,000	110,000	110,000	109,000	88,000	84,000	84,000	65,000	65,000	63,000	63,000	63,000	62,000	62,000	61,000	55,000	45,000	39,000	39,000	38,000	38,000	38,000	38,000	30,000	29,000	26,000				263,000	183,000	183,000	183,000	183,000	178,000	178,000	157,000	155,000	126,000	123,000	116,000	116,000	88,000	87,000	55,000	54,000	41,000	40,000	40,000	40,000	40,000	40,000	40,000	40,000	40,000	40,000	40,000	40,000	31,000	31,000	30,000		25,000	25,000	25,000		25,000	25,000
additional paid-in capital	1,486,947,000	1,474,046,000	1,532,835,000	1,504,671,000	1,591,107,000	1,575,548,000	1,562,027,000	1,554,634,000	1,541,549,000	1,527,544,000	1,516,331,000	1,510,518,000	1,501,639,000	1,484,970,000	1,476,013,000	1,441,868,000	1,386,114,000	1,372,679,000	1,393,947,000	1,352,374,000	1,348,793,000	1,343,279,000	1,245,730,000	1,229,417,000	1,224,228,000	1,161,115,000	1,151,421,000	1,131,241,000	1,124,892,000	1,118,487,000	1,112,321,000	1,107,693,000	1,085,433,000	1,000,177,000	938,159,000	904,957,000	901,075,000	897,027,000	893,278,000	889,698,000	886,575,000	719,966,000	697,149,000	695,058,000	693,066,000	691,419,000	689,729,000	688,390,000	561,687,000	558,766,000	555,010,000	550,729,000	545,767,000	542,934,000	470,849,000	466,276,000	397,996,000	391,925,000	372,105,000	369,686,000	325,492,000	310,756,000	267,583,000	266,127,000	267,115,000	263,806,000	263,135,000	262,579,000	261,862,000	259,843,000	259,068,000	258,266,000	250,770,000	246,358,000	245,669,000	244,787,000	198,809,000	197,620,000	191,099,000	192,840,000	159,173,000	159,126,000	159,120,000	159,074,000	158,691,000	158,473,000
accumulated other comprehensive income	800,000	652,000			514,000																																																											-168,000			-794,000	-354,000	-258,000	353,000	502,000	398,000	248,000	187,000	158,000	172,000
accumulated deficit	-953,726,000	-980,653,000	-999,374,000	-903,275,000	-910,325,000	-927,919,000	-939,305,000	-930,584,000	-930,803,000	-945,096,000	-948,527,000	-924,195,000	-991,928,000	-1,055,737,000	-1,184,492,000	-1,217,351,000	-1,317,130,000	-1,288,700,000	-1,293,173,000	-1,294,064,000	-1,278,597,000	-1,282,998,000	-1,231,419,000	-1,218,824,000	-1,182,068,000	-1,148,609,000	-1,105,896,000	-1,066,224,000	-1,026,255,000	-985,727,000	-946,283,000	-907,325,000	-879,904,000	-857,776,000	-837,458,000	-812,171,000	-790,430,000	-755,736,000	-726,750,000	-699,727,000	-672,865,000	-642,741,000	-619,150,000	-592,933,000	-570,647,000	-540,828,000	-516,051,000	-502,211,000	-489,155,000	-473,480,000	-456,316,000	-435,491,000	-414,948,000	-397,157,000	-382,047,000	-365,542,000	-361,275,000	-346,046,000	-335,411,000	-316,945,000	-301,823,000	-296,825,000	-268,821,000	-259,637,000	-249,038,000	-239,532,000	-243,642,000	-248,743,000	-251,842,000	-246,422,000	-240,343,000	-227,914,000	-215,838,000	-198,737,000	-181,033,000	-167,943,000	-151,488,000	-139,336,000	-124,063,000	-115,891,000	-107,129,000	-98,845,000	-90,266,000	-95,336,000	-90,173,000	-86,140,000
total stockholders’ equity	534,138,000	494,162,000	530,941,000	596,799,000	681,427,000	642,849,000	618,480,000	622,072,000	604,916,000	577,205,000	563,732,000	581,013,000	500,576,000	422,799,000	287,484,000	222,374,000	67,576,000	83,380,000	99,762,000	58,693,000	69,284,000	58,295,000	11,824,000	8,290,000	39,156,000	10,588,000	43,159,000	63,065,000	97,013,000	131,313,000	165,887,000	199,549,000	204,434,000	140,527,000	97,396,000	89,201,000	108,272,000	138,770,000	164,431,000	187,079,000	211,188,000	74,528,000	75,073,000	100,482,000	121,576,000	150,670,000	173,853,000	186,294,000	72,396,000	84,659,000	97,927,000	114,826,000	130,058,000	144,708,000	88,379,000	99,880,000	36,229,000	45,830,000	36,495,000	52,111,000	23,208,000	12,808,000	-1,799,000	6,376,000	17,524,000	24,608,000	20,364,000	13,522,000	9,802,000	13,814,000	19,267,000	30,790,000	35,220,000	47,848,000	64,834,000	77,056,000	47,441,000	58,303,000	66,946,000	74,363,000	49,578,000	57,150,000	65,291,000	59,876,000	64,129,000	67,368,000
total liabilities and stockholders’ equity	946,506,000	918,449,000	945,928,000	986,256,000	1,061,990,000	1,016,321,000	986,565,000	997,096,000	972,933,000	936,432,000	969,922,000	985,850,000	999,337,000	1,022,999,000	1,008,975,000	1,039,246,000	919,711,000	647,909,000	490,119,000	353,272,000	353,395,000	329,314,000	259,256,000	279,068,000	301,015,000	267,081,000	296,600,000	210,884,000	236,388,000	263,863,000	295,333,000	218,785,000	217,827,000	151,968,000	110,132,000	109,680,000	139,298,000	167,613,000	189,644,000	216,633,000	238,907,000	109,494,000	112,169,000	138,290,000	146,896,000	173,465,000	193,585,000	204,622,000	91,698,000	104,012,000	119,621,000	139,752,000	164,822,000	175,895,000	120,676,000	134,102,000	64,719,000	74,430,000	65,507,000	84,249,000	61,790,000	71,678,000	44,284,000	50,470,000	61,644,000	69,148,000	78,144,000									102,890,000			73,471,000	80,093,000	56,702,000	64,339,000	71,250,000
accounts receivables, net of allowance for doubtful accounts of 12,313 at june 30, 2025 and december 31, 2024, respectively		70,699,000
other assets, net of allowance for doubtful accounts of 10,970 at june 30, 2025		64,613,000
convertible notes, current portion, net of debt discount of 188 at june 30, 2025		40,020,000
convertible notes, net of debt discount of 4,248 and 1,646 at june 30, 2025 and december 31, 2024, respectively		220,752,000
accounts receivables, net of allowance for doubtful accounts of 12,313 at march 31, 2025 and december 31, 2024, respectively			54,925,000
other assets, net of allowance for doubtful accounts of 10,970 at march 31, 2025			63,790,000
convertible notes, net of debt discount of 4,701 and 1,646 at march 31, 2025 and december 31, 2024, respectively			260,507,000
accumulated other comprehensive loss			-2,644,000	-4,722,000		-4,911,000	-4,373,000	-2,108,000	-5,959,000	-5,372,000	-4,200,000	-5,438,000	-9,262,000	-6,560,000	-4,163,000						-1,022,000	-2,095,000	-2,575,000	-2,387,000	-3,088,000	-1,983,000	-2,431,000	-2,015,000	-1,687,000	-1,510,000	-213,000	-881,000	-1,156,000	-1,929,000	-3,350,000	-3,624,000	-2,412,000	-2,559,000	-2,135,000	-2,930,000	-2,560,000	-2,727,000	-2,955,000	-1,669,000	-1,106,000	-184,000															-549,000	-1,210,000	-616,000		-36,000	-348,000												-12,000	-120,000					-102,000
accounts receivables, net of allowance for doubtful accounts of 12,313 at december 31, 2024 and december 31, 2023, respectively				45,281,000
other assets				74,760,000	74,458,000	73,671,000	73,452,000	74,325,000	74,154,000	73,915,000	73,941,000	3,311,000	3,337,000	3,363,000	3,447,000	3,398,000	3,623,000	3,838,000	3,668,000	3,573,000	3,238,000	3,181,000	3,301,000	3,344,000	3,509,000	1,799,000	3,104,000	4,976,000	3,834,000	2,104,000	1,267,000	1,270,000	1,270,000	253,000	1,241,000	334,000	330,000	346,000	267,000	231,000	231,000	20,000	20,000	20,000	872,000	876,000	31,000	297,000	302,000	463,000	468,000	473,000	438,000	438,000	438,000	362,000	224,000	224,000	112,000	67,000	2,076,000	2,076,000	1,049,000							3,703,000	4,591,000	5,645,000	2,178,000	155,000	153,000	1,310,000	1,304,000	1,302,000	412,000	412,000	412,000	412,000		402,000	407,000	411,000
convertible notes, net of debt discount of 1,646 and 2,802 at december 31, 2024 and december 31, 2023, respectively				223,854,000
accounts receivables, net of allowance for doubtful accounts of 12,313 at september 30, 2024 and december 31, 2023, respectively					73,334,000
convertible notes, net of debt discount of 1,939 and 2,802 at september 30, 2024 and december 31, 2023, respectively					223,561,000
accounts receivables, net of allowance for doubtful accounts of 12,313 at june 30, 2024 and december 31, 2023, respectively						61,654,000
convertible notes, net of debt discount of 2,228 and 2,802 at june 30, 2024 and december 31, 2023, respectively						223,272,000
accounts receivables, net of allowance for doubtful accounts of 12,313 at march 31, 2024 and december 31, 2023, respectively							44,161,000
convertible notes, net of debt discount of 2,516 and 2,802 at march 31, 2024 and december 31, 2023, respectively							222,984,000
accounts receivables, net of allowance for doubtful accounts of 12,313 and 0 at december 31, 2023 and december 31, 2022, respectively								40,607,000
cepi accrual											47,401,000	107,738,000	107,738,000	107,370,000	107,370,000	128,848,000
convertible notes, net of debt discount of 2,802 and 3,922 at december 31, 2023 and december 31, 2022, respectively								222,698,000
accounts receivables, net of allowance for doubtful accounts of 12,313 and 0 at september 30, 2023 and december 31, 2022, respectively									46,347,000
convertible notes, net of debt discount of 3,085 and 3,922 at september 30, 2023 and december 31, 2022, respectively									222,415,000
accounts receivables, net of allowance for doubtful accounts of 12,313 and 0 at june 30, 2023 and december 31, 2022, respectively										43,245,000
restricted cash										210,000	210,000	207,000	189,000	202,000	214,000	219,000	224,000	229,000	226,000	237,000	226,000	217,000	212,000	216,000	619,000	628,000	615,000	619,000	622,000	624,000	635,000	629,000	626,000	619,000	605,000	602,000	615,000	613,000	617,000	609,000	615,000	613,000	608,000	632,000	642,000	660,000	662,000	662,000	657,000	648,000	644,000	652,000	645,000	640,000	654,000	647,000	659,000	673,000	668,000	652,000	659,000	633,000	656,000	681,000	677,000	667,000	651,000	668,000	674,000	699,000	661,000	408,000	408,000	408,000	408,000	408,000	408,000	408,000	408,000	408,000	408,000	408,000	408,000	408,000	408,000	77,000
convertible notes, net of debt discount of 3,366 and 3,922 at june 30, 2023 and december 31, 2022, respectively										222,134,000
accounts receivables, net of allowance for doubtful accounts of 12,313 and 0 at march 31, 2023 and december 31, 2022, respectively											101,738,000
convertible notes, net of debt discount of 3,645 and 3,922 at march 31, 2023 and december 31, 2022, respectively											221,855,000
accounts receivables												145,130,000	129,772,000	172,270,000	133,968,000	116,216,000
prepaid manufacturing													12,727,000	54,477,000	138,330,000	159,655,000	109,763,000	36,298,000	32,642,000	29,423,000
warrant liability																18,016,000	72,017,000	29,639,000	31,737,000	10,736,000	10,660,000	31,905,000	6,250,000	14,860,000	7,594,000
deferred revenue													87,395,000	191,998,000	313,203,000	349,864,000	358,588,000	129,557,000	52,202,000	38,212,000	21,712,000																																																																1,750,000
convertible notes, net of debt discount of 3,922 and 5,010 at december 31, 2022 and december 31, 2021, respectively												221,578,000
convertible notes, net of debt discount of 4,197 and 5,010 at september 30, 2022, and december 31, 2021, respectively													221,303,000
convertible notes, net of debt discount of 4,470 and 5,010 at june 30, 2022 and december 31, 2021, respectively														221,030,000
convertible notes, net of debt discount of 4,741 and 5,010 at march 31, 2022 and december 31, 2021, respectively															220,759,000
long-term debt																			179,889,000	179,811,000	179,733,000	179,656,000	179,583,000	178,601,000	177,615,000	176,636,000	175,673,000		100,319,000	99,771,000	99,232,000											7,961,000	8,913,000
convertible notes, net of debt discount of 5,010 at december 31, 2021																220,490,000
preferred stock: 0.001 par value
authorized: 5,000 shares; issued and outstanding:
series b convertible preferred stock — no shares and 4 shares at december 31, 2021 and 2020, respectively
accumulated other comprehensive gain																-2,266,000	-1,528,000	-713,000	-1,126,000	273,000																																																									89,000
accounts and other receivables																	200,362,000	105,900,000	83,994,000	22,661,000	35,023,000	903,000	8,135,000	8,886,000	8,822,000	7,582,000	5,791,000	3,704,000	1,507,000	1,304,000	763,000	854,000	783,000	810,000	1,465,000	1,342,000	2,290,000	1,864,000
convertible notes, net of debt discount of 5,277 at september 30, 2021																	220,223,000
long-term deferred revenue																	67,969,000	106,950,000	64,350,000
series b convertible preferred stock ̶ no shares and 4 shares at september 30, 2021 and december 31, 2020, respectively
convertible notes, net of debt discount of 5,541 at june 30, 2021																		219,959,000
series b convertible preferred stock ̶ 4 shares at june 30, 2021 and december 31, 2020
series b convertible preferred stock ̶ 4 shares at march 31, 2021 and december 31, 2020
intangible assets																							202,000	2,500,000	4,823,000	7,147,000	9,445,000	11,717,000	14,041,000	16,364,000	18,662,000	1,306,000
series b convertible preferred stock — 4 shares and 5 shares at december 31, 2020 and 2019, respectively
series b convertible preferred stock ̶ 4 shares and 5 shares at september 30, 2020 and december 31, 2019, respectively
series b convertible preferred stock ̶ 4 shares and 5 shares at june 30, 2020 and december 31, 2019, respectively
series b convertible preferred stock ̶ 5 shares at march 31, 2020 and december 31, 2019
series b convertible preferred stock — 5 shares at december 31, 2019 and no shares at december 31, 2018
series b convertible preferred stock ̶ 5 shares at september 30, 2019 and no shares at december 31, 2018
long term debt																												100,871,000																9,559,000
deferred revenues																																							1,759,000	2,654,000	3,558,000	7,448,000	5,694,000	5,865,000	5,644,000	6,584,000	7,511,000	6,125,000	6,126,000	6,346,000	7,167,000	6,785,000	4,172,000	2,859,000	3,801,000	4,210,000	1,429,000	1,429,000	1,429,000	1,429,000	1,429,000	1,429,000	2,384,000	2,718,000	3,127,000	3,672,000	16,154,000	33,133,000	6,784,000	3,682,000	3,516,000	3,427,000	781,000	548,000	748,000	778,000	1,427,000	829,000	750,000	750,000		48,000		1,000,000
accounts receivable																																							1,164,000	1,394,000	1,163,000	657,000	909,000	727,000	727,000	1,292,000	1,730,000	1,627,000	2,159,000	2,025,000	1,547,000	1,005,000	3,685,000	1,284,000	1,375,000	9,527,000	783,000	1,139,000	1,127,000	1,001,000	1,255,000	1,349,000	1,152,000	895,000	1,184,000	1,519,000	2,978,000	6,407,000	6,216,000	8,057,000	6,140,000	7,234,000	574,000	1,102,000	1,218,000	2,154,000	1,885,000	710,000	421,000	689,000	1,061,000	744,000	8,957,000	3,131,000	3,544,000	4,572,000
deferred revenues, net of current portion																																									6,988,000	3,916,000	6,599,000	6,900,000	855,000	1,710,000	2,823,000	1,173,000
series b convertible preferred stock — no shares at december 31, 2015 and 43 shares at december 31, 2014
series b convertible preferred stock — no shares and 43 shares issued and outstanding at september 30, 2015 and december 31, 2014, respectively
long-term debt, current portion																																										1,498,000	594,000
series b convertible preferred stock — 17 shares at june 30, 2015 and 43 at december 31, 2014
series b convertible preferred stock — 17 shares at march 31, 2015 and 43 at december 31, 2014
series b convertible preferred stock — 43 shares at december 31, 2014 and 2013
other accrued liabilities																																													5,403,000	4,979,000
preferred stock: 0.001 par value:
authorized: 5,000 shares
issued and outstanding: series b convertible preferred stock — 43 shares at september 30, 2014 and december 31, 2013
common stock: 0.001 par value:
authorized: 350,000 shares
issued and outstanding: 262,934 shares at september 30, 2014 and 262,796 shares at december 31, 2013																																													263,000
issued and outstanding: series b convertible preferred stock — 43 shares at june 30, 2014 and december 31, 2013
issued and outstanding: 262,881 shares at june 30, 2014 and 262,796 shares at december 31, 2013																																														263,000
series b convertible preferred stock — 43 shares at march 31, 2014 and december 31, 2013
issued and outstanding: 262,856 shares at march 31, 2014 and 262,796 shares at december 31, 2013																																															263,000
total accumulated other comprehensive loss																																															-88,000	-148,000	-319,000	-810,000	-950,000	-595,000	-939,000	-1,247,000	-580,000	-1,009,000	-618,000	-172,000	-315,000	-746,000
series b convertible preferred stock — 43 shares at december 31, 2013 and zero shares at december 31, 2012
deferred revenues, noncurrent																																																	2,751,000	3,820,000	4,013,000	5,283,000	4,775,000	5,312,000	5,849,000	6,386,000	4,583,000	4,940,000	5,298,000	5,655,000	6,012,000	16,369,000	16,726,000	17,083,000	17,440,000	17,798,000	18,543,000	18,512,000	39,188,000	39,785,000	40,127,000	40,792,000	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000				750,000	750,000	750,000	6,750,000
accumulated other comprehensive loss:
unrealized gain on marketable securities available-for-sale																																																	22,000	4,000	37,000	45,000	29,000			-3,000		2,000	9,000	-17,000						1,000	17,000	49,000		24,000	182,000	138,000	23,000	35,000	16,000	28,000	7,000
cumulative translation adjustment																																																	-341,000	-814,000	-987,000	-640,000	-968,000	-1,217,000	-577,000	-1,006,000	-612,000	-174,000	-324,000	-729,000	-552,000	-1,220,000	-616,000	-168,000	-36,000	-349,000	-811,000	-403,000	-273,000	329,000	320,000	260,000	225,000	152,000	142,000	144,000	82,000	60,000	-5,000		-4,000	-4,000	-4,000
note payable to symphony dynamo holdings llc																																																					14,452,000	13,905,000	13,357,000	12,810,000
dynavax stockholders’ equity:
unrealized loss on marketable securities available-for-sale																																																						-30,000	-3,000		-6,000																					-72,000	-115,000		-96,000	-120,000	-161,000
marketable securities																																																								82,020,000	34,149,000	34,245,000	32,232,000	49,701,000	19,022,000	28,325,000				6,509,000	13,783,000	15,264,000				42,324,000				58,677,000	25,243,000	31,613,000	50,649,000		31,561,000	53,118,000	46,023,000
other intangible assets																																																											54,000	299,000	544,000	789,000	1,034,000	1,279,000	1,524,000	1,769,000	2,014,000	2,259,000	2,504,000	2,749,000	2,994,000	3,239,000	3,627,000	3,879,000	4,130,000	4,382,000	4,633,000	4,884,000
long-term note payable to holdings																																																												10,939,000	10,540,000	10,140,000	9,741,000	9,342,000
long-term contingent liability to holdings																																																									877,000			843,000	944,000	3,161,000	3,109,000	3,040,000
long-term note payable to symphony dynamo holdings llc																																																									12,342,000	11,874,000	11,407,000
long-term contingent liability to symphony dynamo holdings llc																																																										860,000	840,000
other long-term accrued liabilities																																																										642,000
warrant liability to symphony dynamo holdings llc																																																														12,029,000	2,315,000	2,567,000
unrealized gain on marketable securities available for sale																																																													3,000	10,000
dynavax stockholders’ equity
investments held by symphony dynamo, inc.																																																																	21,697,000	22,772,000	23,788,000	25,109,000	26,685,000	28,029,000	29,475,000	31,631,000	32,804,000	35,098,000	8,609,000	13,363,000	17,727,000	19,044,000
liability from program option exercised under the sdi collaboration																																																																	15,000,000	15,000,000	15,000,000	15,000,000	15,000,000	15,000,000	15,000,000	15,000,000	15,000,000	15,000,000
accumulated other comprehensive income:
total dynavax stockholders’ equity																																																																6,376,000	18,082,000	23,966,000	18,739,000
noncontrolling interest in sdi																																																																	-558,000	642,000	1,625,000	2,634,000	3,573,000	5,286,000	6,775,000	8,341,000	10,342,000
liabilities, noncontrolling interest and stockholders’ equity
total liabilities, noncontrolling interest and stockholders’ equity																																																																				90,623,000	87,559,000	96,938,000	105,332,000	120,449,000	87,996,000	98,482,000	87,033,000		75,498,000	76,624,000
unrealized gains on marketable securities available-for-sale																																																																					15,000
inventory																																																																									263,000	248,000	246,000	257,000
commitments and contingencies stockholders’ equity:
noncontrolling interest in symphony dynamo, inc.																																																																										11,963,000		2,016,000	6,457,000	9,728,000
deferred stock compensation																																																																																-2,467,000	-2,383,000	-2,693,000	-3,029,000	-3,366,000	-3,783,000	-4,369,000
accumulated other comprehensive gain:
notes receivable from stockholders																																																																																	-8,000	-339,000	-394,000	-419,000	-631,000	-621,000
liabilities, minority interest, convertible preferred stock, and stockholders’ equity
minority interest in dynavax asia
convertible preferred stock: 0.001 par value...
stockholders’ equity
total liabilities, minority interest, convertible preferred stock, and stockholders’ equity																																																																																				73,646,000	79,073,000	81,014,000
deferred revenue, noncurrent																																																																																					6,250,000
current portion of deferred revenue																																																																																						1,750,000
noncurrent portion of deferred revenue																																																																																						6,500,000
convertible preferred stock

Cashflow Statements:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30

operating activities
net income	26,927,000			7,050,000	17,594,000			219,000	14,293,000	3,431,000	-24,332,000	67,733,000	63,809,000	128,755,000	32,859,000	99,779,000	-28,430,000	4,473,000	891,000	-15,467,000	4,401,000	-51,579,000	-12,595,000								-38,958,000	-27,421,000	-22,128,000	-20,318,000	-25,287,000	-21,741,000	-34,694,000	-28,986,000	-27,023,000	-26,862,000	-30,124,000	-23,591,000	-26,217,000	-22,286,000	-29,819,000	-24,777,000	-13,840,000	-13,056,000	-15,675,000	-17,164,000	-20,825,000	-20,543,000	-17,791,000	-15,110,000	-16,505,000		-15,229,000	-10,635,000	-18,466,000									3,099,000	-5,420,000	-6,079,000	-12,429,000	-12,076,000	-17,101,000	-17,704,000	-13,090,000	-16,455,000	-12,152,000	-15,273,000	-8,172,000	-8,762,000	-8,284,000	-8,579,000	5,070,000	-5,163,000	-4,033,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	1,291,000	1,242,000	1,173,000	1,184,000	1,184,000	1,135,000	1,124,000	1,114,000	1,115,000	1,100,000	1,013,000	837,000	890,000	1,100,000	985,000	1,016,000	1,078,000	1,096,000	1,106,000	1,107,000	1,103,000	1,049,000	1,014,000	1,100,000	4,642,000	1,494,000	1,702,000	1,110,000	853,000	835,000	823,000	788,000	782,000	885,000	789,000	683,000	628,000	544,000	402,000	407,000	324,000	299,000	335,000	388,000	336,000	341,000	339,000	341,000	340,000	327,000	319,000	309,000	306,000	300,000	292,000	294,000	305,000	344,000	360,000	301,000	343,000	372,000	399,000	422,000	475,000	490,000	470,000	489,000	453,000	470,000	438,000	392,000	379,000	371,000	341,000	333,000	1,624,000	-1,011,000	184,000	181,000	191,000	203,000	184,000	229,000	97,000
amortization of right-of-use assets	803,000	797,000	863,000	887,000	870,000	844,000	824,000									702,000	687,000	673,000	653,000	656,000	645,000	627,000	634,000	633,000	696,000	744,000	1,302,000
inventory write off	-338,000	0	3,976,000		0	0	1,264,000
sublease termination loss				49,000	0	0	4,765,000
accretion of discounts on marketable securities	-1,199,000	-1,698,000	-2,137,000		-3,427,000	-3,937,000	-4,528,000		-4,050,000	-3,765,000	-3,498,000											9,000	-87,000		-418,000	-552,000	-323,000		-465,000	-505,000	-176,000
stock-based compensation expense	12,390,000	12,979,000	14,455,000	13,004,000	13,083,000	13,518,000	13,014,000	11,309,000	10,687,000	10,562,000	10,034,000																																		1,586,000	1,676,000	1,270,000						1,903,000	2,069,000	2,322,000		1,287,000	1,167,000	1,480,000		586,000	425,000	541,000	933,000	916,000	667,000	519,000	717,000	1,052,000	775,000	661,000	1,049,000	985,000	689,000	808,000	917,000	970,000
bad debt expense	0	0	10,970,000					0	0	0	12,313,000
non-cash interest expense	-2,513,000	1,642,000	1,691,000	-1,116,000	1,698,000	-1,121,000	1,695,000	-1,126,000	1,690,000	-1,130,000	1,686,000	-1,134,000	1,682,000	-1,140,000	1,680,000	-938,000			414,000	413,000	403,000	388,000	1,338,000	1,440,000	1,398,000	1,321,000	814,000	811,000	805,000	791,000	348,000
loss on debt extinguishment	0	0	82,095,000													0	0
changes in operating assets and liabilities:
accounts and other receivables	24,000	-16,788,000	-9,651,000	28,371,000	-12,647,000	-16,476,000	-1,621,000	2,333,000	-1,513,000	12,112,000	30,336,000	-16,397,000	43,124,000	-37,306,000	-5,120,000	68,546,000	-94,462,000	-21,906,000	-61,333,000	8,362,000	-30,120,000	7,232,000	751,000	-64,000	-1,240,000	-1,791,000	-2,087,000	-2,197,000	-203,000	-541,000	91,000	-71,000	27,000	655,000	-123,000	948,000	-426,000
inventories	2,737,000	-1,284,000	-8,325,000	-9,533,000	60,000	-656,000	-9,780,000	-5,526,000	3,077,000	4,605,000	1,753,000	23,360,000	-43,115,000	5,059,000	-17,703,000	3,374,000	19,154,000	-17,605,000	-5,157,000	-4,656,000	-4,641,000	-6,293,000	-6,767,000	-1,976,000	-2,727,000	-9,060,000	-8,547,000	-6,570,000	-7,340,000	-4,562,000	-238,000
prepaid manufacturing												12,727,000	41,750,000	83,853,000	21,325,000	-49,892,000	-73,465,000	-3,656,000	-3,219,000
prepaid expenses and other current assets	3,335,000	-77,000	-5,518,000	-467,000	3,647,000	-1,490,000	-4,800,000	-23,000	-1,478,000	-1,868,000	-1,304,000	14,375,000	34,534,000	-51,543,000	-9,231,000	-12,671,000	-51,640,000	-76,000	-171,000	9,580,000	-9,323,000	-1,083,000	-1,000,000	-1,669,000	1,034,000	-797,000	154,000	-1,498,000	-721,000	-580,000	394,000	11,000	-199,000	-1,603,000	-39,000	-244,000	600,000	505,000	-301,000	62,000	1,369,000	-380,000	580,000	-480,000	1,400,000	-2,655,000	-948,000	-255,000	121,000	-24,000	835,000	367,000	1,726,000	-2,277,000	-738,000	263,000	395,000	-273,000	-155,000	-281,000	-262,000	-15,000	-216,000	422,000	223,000	-133,000	-107,000	360,000	262,000	67,000	844,000	-111,000	-653,000	-78,000	-1,009,000	444,000	158,000	1,429,000	-1,427,000		330,000	-19,000	-721,000		-113,000
other assets				-312,000	-777,000	-219,000	118,000	-160,000	27,000	26,000	677,000	26,000	26,000	84,000	-49,000	225,000	215,000	-170,000	-95,000	-335,000	-57,000	120,000	43,000	165,000	-1,710,000	1,305,000	1,872,000	-1,142,000	-1,730,000	-837,000	3,000		-1,017,000																																			6,000	26,000	-31,000	-80,000	-96,000	210,000	-2,000	1,157,000	-6,000	-2,000				0	-412,000	402,000		4,000
accounts payable	1,355,000	-1,835,000	-4,668,000	1,876,000	2,592,000	2,071,000	-2,640,000	2,564,000	-461,000	-4,247,000	4,096,000	390,000	-2,018,000	-14,619,000	16,938,000	-222,000	-7,754,000	7,504,000	-295,000	-2,015,000	2,560,000	-1,898,000	-2,095,000	1,813,000	218,000	-1,607,000	4,424,000	1,040,000	754,000	1,274,000	349,000	-416,000	1,435,000	-824,000	-2,110,000	477,000	-900,000	946,000	658,000	973,000	-375,000	-1,395,000	2,043,000	-3,807,000	3,172,000	-42,000	154,000	220,000	36,000	-474,000	-439,000	588,000	423,000	-1,203,000	318,000	727,000	-429,000	-138,000	-449,000	262,000	1,034,000	-58,000	-595,000	649,000	-185,000	134,000	183,000	-225,000	-249,000	-1,385,000	-1,654,000	2,467,000	-1,454,000	1,841,000	-617,000	-927,000	1,691,000	248,000	-6,000		639,000	891,000	-662,000		-102,000
lease liabilities	-999,000	-1,051,000	-1,101,000	-1,167,000	-1,111,000	-1,084,000	-1,025,000	-994,000	-956,000	-886,000	-793,000	-759,000	-688,000	-872,000	-806,000	-818,000	-862,000	-803,000	-751,000	-741,000	-748,000	-711,000	-672,000	-660,000	-579,000	-655,000	-106,000
accrued and other liabilities	-9,984,000	10,783,000	-7,363,000	7,065,000	3,594,000	6,742,000	-6,368,000
net cash from operating activities	33,829,000	23,431,000	-19,639,000	53,011,000	19,467,000	10,713,000	-16,679,000	13,766,000	31,129,000	28,046,000	27,622,000	34,948,000	61,560,000	16,651,000	-50,443,000	120,497,000	66,211,000	110,788,000	38,032,000	-15,743,000	-27,821,000	-21,821,000	-26,866,000	-23,012,000	-21,977,000	-36,361,000	-39,902,000	-33,630,000	-33,872,000	-33,927,000	-29,872,000	-17,749,000	-17,127,000	-17,392,000	-25,250,000	-26,282,000	-28,208,000	-25,427,000	-27,134,000	-21,846,000	-23,002,000	-23,572,000	-24,139,000	-16,867,000	-23,089,000	-22,606,000	-11,176,000	-11,843,000	-12,255,000	-15,689,000	-18,886,000	-7,592,000	-12,347,000	-15,689,000	-8,181,000	-5,288,000	-12,704,000	-9,629,000	-19,495,000	-17,886,000	-12,189,000	-13,793,000	-7,502,000	-9,291,000	-8,842,000	-7,372,000	-8,047,000	3,981,000	1,974,000	-8,725,000	-14,265,000	18,429,000	-17,104,000	-18,458,000	-14,899,000	-17,681,000	-1,644,000	-10,381,000	-7,534,000	-8,495,000	-7,614,000	1,307,000	-8,056,000	-5,306,000	-999,000
capital expenditures	-832,000	-1,798,000	-1,882,000	-2,517,000	-1,158,000	-560,000	-394,000	-2,128,000	-183,000	-1,137,000	-357,000	-1,545,000	-1,522,000	-3,706,000	649,000	-4,006,000	-4,199,000	655,000	-1,336,000	-772,000	-25,000	-970,000	-1,944,000	-2,268,000	-12,972,000	-7,501,000	-3,882,000	-1,349,000	-1,199,000	-742,000	-897,000	-295,000	-132,000	-8,000	-234,000	-1,241,000	-1,600,000	-2,305,000	-2,611,000	-2,724,000	-2,578,000	-1,050,000	-618,000	0	-288,000	-521,000	-398,000	-313,000	-488,000	-293,000	-535,000	-1,204,000	-324,000	-471,000	-932,000	-564,000	-159,000	-278,000	-141,000	-287,000	-94,000	-433,000	394,000	71,000	-378,000	-505,000	435,000	230,000	444,000	-1,374,000	-3,398,000	0	0	0	-711,000	-647,000	0	0	-39,000	-110,000	-89,000	-282,000	-81,000	-209,000	-1,190,000
free cash flows	32,997,000	21,633,000	-21,521,000	50,494,000	18,309,000	10,153,000	-17,073,000	11,638,000	30,946,000	26,909,000	27,265,000	33,403,000	60,038,000	12,945,000	-49,794,000	116,491,000	62,012,000	111,443,000	36,696,000	-16,515,000	-27,846,000	-22,791,000	-28,810,000	-25,280,000	-34,949,000	-43,862,000	-43,784,000	-34,979,000	-35,071,000	-34,669,000	-30,769,000	-18,044,000	-17,259,000	-17,400,000	-25,484,000	-27,523,000	-29,808,000	-27,732,000	-29,745,000	-24,570,000	-25,580,000	-24,622,000	-24,757,000	-16,867,000	-23,377,000	-23,127,000	-11,574,000	-12,156,000	-12,743,000	-15,982,000	-19,421,000	-8,796,000	-12,671,000	-16,160,000	-9,113,000	-5,852,000	-12,863,000	-9,907,000	-19,636,000	-18,173,000	-12,283,000	-14,226,000	-7,108,000	-9,220,000	-9,220,000	-7,877,000	-7,612,000	4,211,000	2,418,000	-10,099,000	-17,663,000	18,429,000	-17,104,000	-18,458,000	-15,610,000	-18,328,000	-1,644,000	-10,381,000	-7,573,000	-8,605,000	-7,703,000	1,025,000	-8,137,000	-5,515,000	-2,189,000
investing activities
purchases of marketable securities	-139,862,000	-18,096,000	-93,697,000	-33,016,000	-164,926,000	-175,436,000	-150,685,000	-152,881,000	-224,509,000	-74,230,000	-185,301,000	-117,630,000	-201,016,000	-63,285,000	-250,375,000	-1,000	1,000	-92,912,000	-72,016,000	-29,804,000	-68,800,000	-85,197,000	-17,985,000	-34,043,000	-72,807,000	-79,136,000	-29,205,000	-25,996,000	-987,000	-45,718,000	-141,103,000	-34,988,000	-99,639,000	-48,393,000	-44,652,000	-4,727,000	-23,919,000	-37,051,000	-61,057,000	-81,018,000	-109,264,000	0	-18,654,000	0	-7,556,000	-23,432,000	-13,819,000	-143,471,000	-19,046,000	-16,073,000	-13,454,000	-36,515,000	-55,234,000	-81,564,000	-32,836,000	-73,198,000	-18,498,000	-18,505,000	-1,004,000	-49,941,000	-2,537,000			0	-2,000	-2,016,000	-12,271,000	-12,673,000	-9,662,000	-7,494,000	-5,926,000	-38,753,000	-975,000	-24,414,000	-16,090,000	-46,215,000	-11,974,000	0	-7,653,000	-44,811,000	-3,491,000	-20,021,000	-15,691,000
proceeds from maturities and redemption of marketable securities	168,422,000	114,340,000	104,535,000		150,807,000	147,448,000	154,265,000
purchases of property and equipment	-1,237,000	-1,452,000	-3,928,000	-3,478,000	-1,346,000	-779,000	-749,000	-1,723,000	-347,000	-751,000	-1,283,000	-1,587,000	-1,281,000	-2,913,000	-1,358,000	-3,036,000	-3,629,000	-1,065,000	-1,747,000	-769,000	-265,000	-686,000	-2,352,000	-1,831,000	-9,187,000	-7,501,000	-3,882,000	-1,349,000	-1,199,000	-742,000	-897,000	-295,000	-132,000	-8,000	-234,000	-1,241,000	-1,600,000	-2,305,000	-2,611,000	-2,724,000	-2,578,000	-1,050,000	-618,000					-313,000	-488,000	-293,000	-535,000	-1,204,000	-324,000	-471,000	-932,000	-564,000	-159,000	-278,000	-141,000	-287,000	-94,000	-433,000	394,000	71,000	-378,000	-505,000	435,000	230,000	444,000	-1,374,000	-3,398,000				-711,000	-647,000			-39,000	-110,000	-89,000	-282,000	-81,000	-209,000	-1,190,000
net cash from investing activities	27,323,000	94,792,000	6,910,000	23,366,000	-15,465,000	-28,767,000	2,831,000	-20,242,000	-106,074,000	24,722,000	-52,334,000	-32,967,000	-119,047,000	52,502,000	-216,483,000	54,938,000	45,672,000	-63,752,000	-22,633,000	14,342,000	-2,054,000	-49,383,000	10,563,000	24,851,000	-40,219,000	-42,027,000	14,613,000	44,412,000	43,564,000	27,175,000	-59,685,000	6,057,000	-82,348,000	-25,401,000	-7,011,000	28,122,000	25,981,000	11,394,000	20,752,000	-36,552,000	-63,507,000	24,785,000	-10,522,000	37,111,000	25,862,000	12,892,000	14,732,000	-102,568,000	6,660,000	8,205,000	36,351,000	4,583,000	1,442,000	-39,375,000	-6,343,000	-48,722,000			17,000,000			-28,790,000	394,000	1,700,000	7,195,000	7,745,000	3,235,000	1,634,000	7,125,000	7,728,000	13,629,000	-20,813,000	21,592,000	-18,028,000	13,652,000	-29,248,000	7,264,000	-13,990,000	15,594,000	-35,104,000	21,282,000	-7,658,000	2,773,000	-49,846,000	-1,190,000
financing activities
proceeds from issuance of convertible notes	0	0	39,708,000													0	0
payment for debt issuance costs	0	-562,000	-3,938,000
payments for debt extinguishment	0	0	-80,938,000
proceeds from unwind of capped call options	0	0	46,554,000
payments for repurchase of common stock	-572,000	-71,170,000	-29,465,000
proceeds from exercise of stock options	95,000	235,000	6,503,000		1,871,000	419,000	1,635,000																																														446,000	272,000	1,071,000			0	65,000		28,000	40,000	3,000	9,000	0			0	0	0	5,000		0	0	22,000
proceeds from employee stock purchase plan	664,000	0	835,000	0	856,000	0	904,000	0	758,000	0	777,000	1,000	720,000	0	710,000	0	458,000	0	383,000	0	361,000	0	311,000	0	158,000	0	407,000	0	339,000	0	255,000	1,000	137,000	0	155,000	-1,000	355,000	0	261,000	0	188,000	0	103,000	0	60,000	1,000	69,000	0	77,000	0	147,000	0	179,000	0	128,000	0	92,000	0	40,000	0	30,000	0	42,000	0	35,000	0	37,000	0	68,000	0	136,000	0	78,000	0	71,000	0	57,000	0	57,000	-1,000	49,000	0	66,000
payments for taxes related to net share settlement of restricted and performance stock units	-248,000	-421,000	-11,141,000
net cash from financing activities	-61,000	-71,918,000	-31,882,000	-98,875,000	2,476,000	-1,415,000	-4,203,000	1,776,000	2,994,000	-294,000	-3,090,000	153,000	8,057,000	1,028,000	10,287,000	14,816,000	5,322,000	3,335,000	32,303,000	66,000	1,412,000	93,482,000	14,539,000	0	65,744,000	345,000	88,262,000	6,000	359,000	-123,000	98,829,000	18,078,000	81,712,000	58,665,000	29,387,000	-216,000	387,000	24,000	336,000	300,000	153,006,000	20,514,000	139,000	9,758,000	60,000	14,000	69,000	125,290,000	76,000	20,000	15,000	-14,178,000	930,000	70,037,000	2,253,000	67,054,000	4,787,000	18,660,000	939,000	43,364,000	2,122,000	41,229,000	916,000	19,708,000	2,310,000	4,000	37,000	0	-749,000	0	2,141,000	2,000,000	3,578,000	30,000,000	74,000	45,070,000	219,000	17,554,000	57,000	33,157,000	384,000	66,000	98,000	228,000	-256,000
effect of exchange rate changes on cash and cash equivalents, and restricted cash	55,000	1,100,000	458,000	-960,000	363,000	-64,000	-201,000	479,000	-305,000	-1,000	151,000
net increase in cash and cash equivalents, and restricted cash	61,146,000
cash and cash equivalents, and restricted cash at beginning of period	0	0	96,154,000		0	0	150,556,000		0	0	202,211,000
cash and cash equivalents, and restricted cash at end of period	61,146,000	47,405,000	52,001,000		6,841,000	-19,533,000	132,304,000		-72,256,000	52,473,000	174,560,000
supplemental disclosure of cash flow information
cash paid during the period for income taxes	455,000	1,737,000	413,000		1,614,000	2,014,000	949,000		703,000	678,000	32,000		279,000	422,000	87,000
cash paid during the period for interest	0	503,000	1,518,000		0				0				0				4,912,000	-2,243,000	4,296,000		4,392,000	4,345,000	3,412,000		3,415,000	3,360,000	1,940,000		1,930,000	1,900,000	813,000
non-cash investing and financing activities:
purchases of property and equipment, not yet paid	405,000	-346,000	2,046,000	961,000	188,000	219,000	355,000	-405,000	164,000	-386,000	926,000	42,000	-241,000	-793,000	2,007,000	-970,000	-570,000	1,720,000	411,000	-3,000	240,000	-284,000	408,000	-437,000	-3,785,000
right-of-use assets obtained in exchange of operating lease liabilities									431,000	623,000	278,000
net loss			-96,099,000				-8,721,000																	-36,756,000	-33,459,000	-42,713,000	-39,672,000	-39,969,000	-40,528,000
adjustments to reconcile net loss to net cash from operating activities:
net decrease in cash and cash equivalents, and restricted cash			-44,153,000	-23,458,000			-18,252,000				-27,651,000
inventory write-off												19,803,000
amortization of premiums (accretion of discounts) on marketable securities
change in fair value of warrant liability												0	0	0	-1,801,000	-19,222,000	45,121,000	-2,097,000	25,552,000	76,000	-21,245,000	25,655,000	-8,610,000
gain on sale of assets								0				0	0			0				0
cepi accrual												0	368,000	0	-21,478,000
deferred revenue												-87,395,000	-104,603,000	-121,205,000	-36,661,000	-8,724,000	229,031,000	13,005,000	78,340,000	16,500,000																																																																	-250,000
proceeds from maturities and redemptions of marketable securities												86,250,000	83,250,000	117,700,000	35,250,000	57,975,000	48,300,000	30,225,000	51,130,000	30,915,000	43,250,000	36,500,000	37,900,000
proceeds from sale of assets, net of transaction costs												0				0				3,992,000
proceeds from warrants exercises														0	8,455,000	13,556,000	882,000
proceeds from exercise of stock options and/or release of restricted stock awards								2,021,000	2,722,000	1,378,000	239,000				1,122,000
payments for taxes related to net share settlement of rsus								-245,000	-486,000	-1,672,000	-4,106,000
cash and cash equivalents, and restricted cash at beginning of year
cash and cash equivalents, and restricted cash at end of year
cash paid during the year for income taxes
cash paid during the year for interest																																								0	287,000	249,000	184,000
reclassification of contract asset from other current assets to other assets								0	0	0	71,307,000
reclassification of cepi accrual to cepi accrual long-term								0	0	0	-60,337,000
advance payments forgiven per cepi-bio e assignment agreement								0	0
right-of-use assets obtained in exchange for operating lease liabilities																								1,522,000	4,297,000	0	34,807,000
proceeds from sale of assets
payments for taxes related to net share settlement of restricted stock units					-251,000	-1,834,000	-6,742,000
proceeds from issuances of common stock
purchases of capped call options																0	0
repayment of long-term debt																0	0
amortization of right-of-use assets and loss on disposal of property and equipment									755,000	693,000	642,000		600,000	901,000	743,000
accrued liabilities and other liabilities									8,943,000	7,413,000	-5,001,000		3,574,000	16,972,000	-39,589,000		62,330,000	10,604,000	-2,847,000		10,023,000	373,000	-3,728,000		-3,777,000	4,304,000	-7,878,000
proceeds from maturities of marketable securities									117,782,000	99,703,000	134,250,000														41,775,000	44,610,000	54,700,000	71,757,000	47,250,000	73,635,000	91,815,000	41,340,000	17,423,000	23,000,000	37,875,000	34,090,000	51,500,000	50,750,000	84,420,000	47,190,000	48,335,000	25,835,000	8,750,000	37,571,000	33,706,000	36,845,000	28,949,000	41,216,000	26,194,000	24,571,000	50,340,000	42,302,000	57,000,000	42,660,000	27,425,000	25,054,000	18,308,000	16,222,000	18,145,000	19,000,000				0	6,500,000	9,250,000	13,750,000	12,501,000	15,000,000	15,150,000	16,750,000	18,100,000	21,000,000
adjustments to reconcile net income to net cash provided by (used in) operating activities:
loss on disposal of property and equipment and from lease termination
realized gain on available-for-sale securities																				-1,000
stock compensation expense												8,727,000	8,613,000	7,929,000	7,646,000	6,162,000	5,376,000	5,024,000	4,723,000	3,516,000	4,102,000	4,088,000	1,778,000	5,189,000	4,748,000	9,349,000	6,170,000	6,343,000	6,046,000	6,290,000	4,799,000	4,073,000	3,660,000	3,363,000	3,821,000	4,096,000	3,662,000	3,124,000	3,244,000	2,814,000	2,630,000	1,918,000	1,954,000					1,493,000	2,845,000	3,736,000	4,266,000
cost of sales - amortization of intangible assets																				0	0	202,000	2,298,000	2,323,000	2,324,000	2,297,000	2,273,000	2,324,000	3,823,000	2,298,000	2,417,000
tenant improvements provided by the landlord																				229,000	0	0	908,000	360,000	3,411,000
acquisition of technology licenses																				0	0	0	-7,000,000	0	0	0	-7,000,000	0	-1,500,000	0	-9,500,000
proceeds from sales of marketable securities																				10,008,000																																																0	-1,000	0	4,047,000
proceeds from exercise of stock options and release of restricted stock awards												152,000	7,337,000
amortization of premium (accretion of discounts) on marketable securities																	73,000	148,000	221,000
long-term deferred revenue																	-38,981,000
proceeds from issuance of common stock																	0	0	28,156,000		840,000	93,468,000	14,229,000		51,999,000	326,000	13,623,000						80,987,000	58,665,000	29,535,000						163,686,000
proceeds from warrants exercised
effect of exchange rate changes on cash, cash equivalents and restricted cash													-1,098,000	-523,000	-134,000	-418,000	-467,000	185,000	-731,000	731,000	675,000	313,000	-225,000	345,000	-485,000	148,000	-192,000	-155,000	-67,000	-477,000	217,000
net increase in cash, cash equivalents and restricted cash													-50,528,000	69,658,000	-256,773,000	189,833,000	116,738,000	50,556,000	46,971,000			22,591,000	-1,989,000	2,184,000	3,063,000	-77,895,000	62,781,000	10,633,000	9,984,000	-7,352,000	9,489,000
cash, cash equivalents and restricted cash at beginning of period													0	0	436,408,000		0	0	32,310,000		0	0	40,100,000		0	0	49,967,000		0	0	27,213,000
cash, cash equivalents and restricted cash at end of period													-50,528,000	69,658,000	179,635,000		116,738,000	50,556,000	79,281,000		-27,788,000	22,591,000	38,111,000		3,063,000	-77,895,000	112,748,000		9,984,000	-7,352,000	36,702,000
right-of-use assets obtained in exchange of lease liabilities													708,000	594,000	1,173,000
remeasurement of operating lease right-of-use assets for lease modification
(accretion of discounts) amortization of premium on marketable securities														-317,000	-181,000
gain on disposal of property and equipment and from lease termination																					0	0	-76,000
proceeds from long-term debt																								0	0	0	74,250,000	0	0	0	99,000,000
proceeds from issuances of preferred stock
proceeds from exercise of stock options and restricted stock awards																1,260,000	3,982,000				211,000																32,000	24,000	75,000	294,000	128,000	99,000	10,000	36,000	0			82,000	0	20,000	10,000
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
proceeds allocated to warrant liability at issuance																								0
interest expense
proceeds from exercise of warrants																			3,377,000																					6,000	-6,000	202,000	26,000										300,000	151,000	1,054,000		0
proceeds (tax withholding) from exercise of stock options and restricted stock awards																			387,000					0	1,000
(gain) loss on disposal of property and equipment and from lease termination
non-cash acquisition of technology license																												0	0	0	12,773,000
proceeds from issuance of preferred stock
net decrease in cash, cash equivalents and restricted cash
(tax withholding) from exercise of stock options and restricted stock awards																							-1,000
loss on disposal of property and equipment																																																																																				0	1,000
accretion of discounts and amortization of premiums on marketable securities																																-89,000	-69,000	-25,000	-10,000	23,000	32,000	48,000	75,000		162,000
reversal of deferred rent upon lease amendment																																0	0
accrued liabilities and other long-term liabilities
release of accrual for litigation settlement and insurance recovery																																925,000	0	0	4,050,000
revaluation of warrant liability
disposal of fully depreciated property and equipment																									8,437,000	130,000	851,000	0	157,000	5,000	37,000					1,194,000	2,000	4,000	1,154,000	1,265,000	167,000	0	4,000	166,000	11,000	390,000	274,000	78,000	0	7,000	1,000	140,000	10,000	14,000	5,000				836,000					308,000	52,000	63,000	792,000					212,000	2,000	6,000	18,000	140,000
tax withholding from exercise of stock options and restricted stock awards																											-18,000			-123,000	-426,000
write-off of assets in progress
cash-settled portion of stock compensation expense
accrued liabilities and other long term liabilities																												6,433,000	4,834,000	1,054,000	276,000	4,472,000	390,000	-301,000	-1,363,000	-11,473,000	2,874,000	656,000	-3,816,000	8,653,000	2,998,000	-277,000	-2,357,000	476,000	1,117,000	4,888,000	-1,671,000	198,000	269,000	-853,000	-1,905,000	905,000	1,831,000	1,024,000	-1,844,000	830,000	191,000	-403,000	-2,785,000	-6,566,000	2,886,000	3,997,000	3,064,000		674,000	-142,000	83,000
deferred revenues																																				0	0	-1,759,000	-895,000	-7,892,000	-818,000	-929,000	-472,000	6,266,000	-1,795,000	-2,040,000	3,036,000	-1,579,000	-1,289,000	-1,014,000	-888,000	3,121,000	776,000	-1,479,000	-946,000	4,584,000	-357,000	-358,000	-357,000	-357,000	-10,357,000	-1,312,000	-691,000	-766,000	-903,000	-13,227,000	-16,948,000	5,673,000	2,505,000	-176,000	-576,000	33,438,000	233,000	-200,000	-30,000	-649,000	10,598,000				-48,000	48,000	-7,000,000
(tax withholding) proceeds from exercise of stock options and restricted stock awards																												6,000						0	-303,000
accrual for litigation settlement and insurance recovery																																				925,000	0
return of unused development funding to astrazeneca ab
milestone payment from astrazeneca ab
gain on disposal of property and equipment																																	-8,000	-3,000	-21,000										0	-4,000	-20,000	14,000	0																												0	0	-50,000
common stock issuance costs - cash not paid as of period end
(gain) loss on disposal of property and equipment
accretion of debt discount related to debt financing																																								0	-15,000	-49,000	-51,000
amortization of intangible assets																																																								0	0	54,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	249,000	252,000	251,000	252,000	251,000	251,000
loss on extinguishment of debt																																								0
restricted cash and other assets																																			-907,000	-4,000	16,000	-79,000	-36,000	0				852,000	4,000	-845,000	266,000	10,000	152,000	1,000	13,000	-42,000	-5,000	14,000	-83,000	-126,000	14,000	-117,000	-61,000	2,016,000	-26,000	-1,004,000	-1,024,000		-10,000	-16,000	17,000
payment of debt																																								2,000
proceeds (withholding) from exercise of stock options and restricted stock awards
effect of exchange rate changes on cash and cash equivalents																																102,000	184,000	331,000	57,000	-356,000	74,000	-62,000	92,000	-121,000	48,000	46,000	-276,000	-147,000	-209,000	-18,000	3,000
net increase in cash and cash equivalents																																				1,268,000				-58,219,000			-34,798,000	29,855,000	2,624,000	-9,718,000	3,628,000	10,931,000	-5,394,000	-7,431,000	17,417,000													11,985,000	976,000	839,000	-5,183,000	5,485,000	7,748,000	-988,000	1,565,000	-349,000	8,139,000	-6,476,000	-1,175,000	-1,797,000			8,117,000	-10,443,000	14,052,000	-6,285,000	-5,189,000	-54,924,000	-2,445,000
cash and cash equivalents at beginning of year																																																0	0	0	7,599,000
cash and cash equivalents at end of year																																																10,931,000	-5,394,000	-7,431,000	25,016,000
net change in unrealized gain on marketable securities																																-52,000	14,000	-16,000	-29,000	-15,000	-61,000	-41,000	109,000	7,000	5,000	-9,000	8,000	-37,000	-1,000	1,000	69,000	-53,000	18,000	-33,000	-8,000	16,000	59,000								-7,000
cash-settled portion of stock-based compensation expense																																					0	274,000	328,000	0	0
net decrease in cash and cash equivalents																																			-2,817,000			-14,071,000	-5,954,000														-9,880,000	14,777,000	-12,188,000				-1,482,000		-844,000	-1,027,000	-6,640,000
cash and cash equivalents at beginning of period																																	0	0	24,289,000		0	0	44,812,000		0	0	49,511,000		0	0	23,122,000						0	0	31,941,000		0	0	22,453,000		0	0	36,720,000		0	0	28,103,000		0	0	14,293,000		0	0	14,154,000		0	0	8,725,000		0	0	16,590,000
cash and cash equivalents at end of period																																	-17,579,000	16,203,000	21,472,000		-1,766,000	-14,071,000	38,858,000		66,545,000	21,773,000	14,713,000		2,624,000	-9,718,000	26,750,000						-9,880,000	14,777,000	19,753,000		-8,407,000	6,508,000	20,971,000		-844,000	-1,027,000	30,080,000		976,000	839,000	22,920,000		7,748,000	-988,000	15,858,000		8,139,000	-6,476,000	12,979,000		5,861,000	-6,752,000	16,842,000		14,052,000	-6,285,000	11,401,000
unoccupied facility expense																																													131,000	178,000	77,000	8,000
(withholding) proceeds from exercise of stock options and restricted stock awards
return of unused development funding to astrazeneca ab “astrazeneca”
milestone payment from astrazeneca
accretion of end of term payment related to debt financing																																										50,000	57,000
accounts receivable																																							230,000	-231,000	-506,000	252,000	-182,000	0	565,000	438,000	-103,000	532,000	-134,000	-478,000	-542,000	2,680,000	-2,401,000	91,000	8,152,000	-8,744,000	356,000	-12,000	-126,000	254,000	94,000	-197,000	-257,000	289,000	335,000	1,459,000	3,429,000	-191,000	1,841,000	-1,917,000	1,094,000	-6,660,000	528,000	116,000	936,000	-269,000	-1,175,000	197,000	271,000		-317,000	8,213,000	-5,826,000		1,028,000
accretion of discounts and amortization of premiums of marketable securities																																											171,000	167,000	214,000	236,000	264,000	231,000	162,000	250,000	280,000	328,000	332,000	334,000	304,000
proceeds from long-term debt payable to hercules
loss on lease
interest associated with long-term note payable to symphony dynamo holdings llc
payment of notes payable to holdings
purchases of property and equipment, net of proceeds from asset disposals																																													-288,000	-521,000	-398,000
payment of issuance costs
proceeds from issuances of common stock and warrants, net of issuance costs																																																			-142,000
fair value adjustment of the warrant and contingent liabilities to holdings, including the impact of the anti-dilution provision associated with the common stock and warrants issued to symphony capital partners, l.p. and symphony strategic partners, llc
proceeds from issuances of warrants
interest associated with long-term note payable to holdings
payments and proceeds from issuances of common stock and warrants, net of issuance costs																																																	-1,000
effect of exchange rate on cash and cash equivalents																																																	125,000	33,000	-63,000	136,000	95,000	-196,000	83,000	-175,000	-155,000	38,000	74,000	-6,000	104,000	327,000	-448,000	-132,000	313,000	462,000	-408,000	-130,000	-602,000	9,000	60,000	35,000	73,000	10,000	-2,000	62,000	22,000			-1,000	0	0	-4,000
shares issued to aspire capital in conjunction with purchase agreement
shares issued in conjunction with the symphony dynamo, inc. (“sdi”) transaction
warrants issued in conjunction with the sdi transaction
gain on disposal of assets
non-cash interest associated with the note payable to holdings																																																					547,000	548,000	547,000
fair value adjustment of the warrant and contingent liabilities to holdings
proceeds from offering of common stock, net of issuance costs
(gain)/loss on disposal of assets																																																									0
proceeds from issuance of common stock, net of issuance costs																																																									4,591,000	18,653,000	834,000	43,275,000	2,064,000	42,108,000	-48,000	-33,000																				-79,000	75,000
net income attributable to dynavax																																																												-15,122,000	-4,998,000	-28,004,000	-9,184,000	-30,270,000	-9,506,000	4,110,000	5,101,000
consideration paid in excess of carrying value of the noncontrolling interest in sdi
amount attributed to noncontrolling interest in sdi																																																																-1,041,000	-1,200,000	-983,000	-1,009,000	-939,000
non-cash interest associated with long-term note payable to holdings																																																								468,000
fair value adjustment of the warrant and contingent liabilities to holdings, including the impact of the anti-dilution provision associated with the common stock and warrants issued to symphony
interest associated with deerfield financing agreement																																																																0							1,323,000
change in investments held by sdi																																																																1,629,000	1,075,000	1,016,000	1,321,000	1,576,000	1,344,000	1,446,000	2,156,000
cash acquired from the purchase of noncontrolling interest in sdi
note payable issued to holdings from purchase option exercised under the sdi collaboration
shares issued in conjunction with the sdi transaction
liability from program option exercised under the sdi collaboration																																																																									0
modification of warrants previously issued to deerfield																																																																				9,000
fair value adjustments to the common stock, warrant and contingent liability issued to holdings
accretion and amortization of marketable securities																																																									278,000	263,000	354,000	242,000	83,000
proceeds from the sale of property and equipment
proceeds from exercise of stock options and delivery of restricted stock units
disposal of fully depreciated assets																																																									0
net change in unrealized losses on marketable securities
non-cash interest associated with long-term note payable to symphony dynamo holdings llc																																																										467,000	468,000
fair value adjustment of the warrant and contingent liabilities to symphony dynamo holdings llc																																																										20,000	-3,000
net cash provided (used) by investing activities
fair value adjustment of the warrant and contingent liabilities to holdings, including the impact of the anti-dilution provision associate with the common stock and warrants issued to symphony
loan forgiveness																																																																				0
proceeds from notes payable issued to deerfield																																																																				0	0	0	2,000,000
repayment of notes payable issued to deerfield																																																																				0
non-cash interest associated with deerfield financing agreement
non-cash interest associated with note payable to holdings																																																													400,000
fair value of the common stock, warrants and contingent liability issued to holdings
net cash (used in ) provided by investing activities
fair value of the common stock, warrant, and contingent liability to holdings
interest associated with note payable to holdings																																																															399,000
change in the fair value of the warrant and contingent consideration to holdings																																																															-183,000
proceeds from issuance of common stock under equity distribution agreement, net of issuance costs																																																															919,000
accretion and amortization on marketable securities																																																																0	10,000	24,000	-30,000	-100,000	-88,000	-202,000	-331,000	-277,000	-339,000	-551,000	-688,000	-448,000	-17,000	60,000	109,000		210,000	322,000	318,000
inventory																																																																								263,000	-15,000	-2,000	11,000
accrued liabilities																																																																				-5,161,000	1,152,000	114,000	-2,234,000	900,000	1,136,000	-152,000	-954,000	3,812,000	-319,000	1,486,000	868,000		-639,000	309,000	-131,000		1,650,000
proceeds from purchase of noncontrolling interest by preferred shareholders in sdi, net of fees
non-cash activities:
note payable to holdings from purchase option exercised under the sdi collaboration
warrants issued in conjunction with the deerfield financing agreement
loss on the disposal of assets
acquired in-process research and development																																																																												0	0
realized loss on investments																																																																															23,000
cash paid for acquisition, net of cash acquired																																																																												0	0
proceeds from purchase of noncontrolling interest by shareholders in sdi, net of fees
loss on disposal of assets																																																																					23,000
interest expense associated with deerfield financing agreement																																																																					6,885,000
proceeds from the purchase of noncontrolling interest in sdi, net of fees
supplemental disclosure of non-cash flow information
warrants issued in conjunction with deerfield financing agreement
amount attributed to noncontrolling interest in symphony dynamo, inc.																																																																						-1,489,000	-1,566,000	-2,001,000	-1,621,000
realized gain on investments
interest accrued on notes receivable from stockholders																																																																																0	-4,000	-5,000	-7,000	-9,000	-9,000
purchases of investments held by sdi
exercise of stock options																																																																												1,029,000	162,000			13,000	0	-194,000	200,000
repayment of notes receivable from stockholders																																																																																8,000	335,000	60,000	32,000	221,000	0
liability from program option exercised under the sdi transaction
repurchase of common stock for exercise of stock options																																																																																0	0	0	-200,000
realized loss on sale of marketable securities																																																																													0
increase in interest payable
purchases disposal of property and equipment
proceeds from deerfield financing agreement
issuance cost associated with common stock offering																																																																									0	0	-19,000
supplemental disclosure of non-cash investing and financing activities
warrants issued in conjunction with sdi transaction
change in investments held by symphony dynamo, inc.																																																																										-26,489,000	4,754,000
(purchases) disposal of property and equipment
proceeds from purchase of noncontrolling interest by preferred shareholders in symphony dynamo, inc., net of fees																																																																													0
warrants issued in conjunction with the symphony dynamo, inc. transaction																																																																												0	0
loss attributed to noncontrolling interest in symphony dynamo, inc.																																																																											-2,016,000		-3,271,000
maturities and sales of marketable securities																																																																											25,699,000	13,250,000	18,440,000	19,019,000	23,286,000	9,817,000	24,862,000	12,645,000	18,545,000
purchases of investments held by symphony dynamo, inc.																																																																												4,364,000	1,317,000
proceeds from purchase of noncontrolling interest by shareholders in symphony dynamo, inc., net of fees
restricted cash																																																																																				0	-331,000
change in unrealized gain on marketable securities
lease incentive
conversion of preferred stock upon initial public offering
conversion of ordinary shares in dynavax asia upon initial public offering
interest accrued on notes receivable
change in unrealized loss on marketable securities																																																																													79,000
change in cumulative translation adjustment																																																																													22,000			-1,000	0	0	-4,000
disposal (purchases) of property and equipment
net increase increase in cash and cash equivalents
adjustments to reconcile net income (income) to net cash from operating activities:
amortization of stock-based compensation expense																																																																															666,000	439,000	308,000	336,000	317,000	793,000	728,000
net change in unrealized loss on marketable securities																																																																															29,000	-48,000
realized loss on investment
proceeds from issuance of ordinary shares in dynavax asia, net of issuance costs
repurchase of common stock
repurchase of common stock for notes receivable
deemed dividend upon issuance of ordinary shares of dynavax asia
conversion of ordinary shares in dynavax asia upon initial public offering.
net unrealized loss on marketable securities																																																																																		41,000	-59,000
proceeds from issuance of preferred stock, net of issuance costs
repayments of equipment financing
accretion and amortization on investments																																																																																					0
purchase of marketable securities
maturities and sale of marketable securities																																																																																					0
cash and cash equivalents at beginning of the period																																																																																					0
cash and cash equivalents at end of the period																																																																																					-2,445,000
interest paid
net unrealized gain on marketable securities
issuance of common stock for notes receivable
marketable securities, at cost
unrealized gains

Dynavax Technologies Corporation(NASDAQ:DVAX)

Dynavax Technologies Corporation
(NASDAQ:DVAX)